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 Abstract Background 
The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis and malaria 
through the formulation of Millennium Development Goal 6 (MDG 6).  The Global Burden of Disease 
2013 study provides a consistent and comprehensive approach to disease estimation 1990 to 2013, and 
an opportunity to assess if there has been accelerated progress since the Millennium Declaration.   Methods 
To estimate incidence and mortality for HIV, we used the UNAIDS Spectrum model appropriately 
modified based on a systematic review of the literature on mortality with and without antiretroviral 
therapy (ART). For concentrated epidemics, we calibrated Spectrum models to fit vital registration data 
corrected for misclassification of HIV deaths. In generalized epidemics, we minimized a loss function to 
select epidemic curves most consistent with prevalence data and demographic data on all-cause 
mortality. We analyzed counterfactual scenarios for HIV to assess years of life saved through prevention 
of mother to child transmission (PMTCT) and ART. For tuberculosis, we analyzed vital registration and 
verbal autopsy data to estimate mortality using cause of death ensemble modeling. We analyzed data 
on corrected case-notifications, expert opinions on the case-detection rate, prevalence surveys and 
estimated cause-specific mortality using Bayesian meta-regression to generate consistent trends in all 
parameters. Malaria mortality and incidence were analyzed using an updated cause of death database, a 
systematic analysis of verbal autopsy validation studies for malaria and recent literature on incidence, 
drug resistance and coverage of insecticide treated bed nets. Findings 
Globally in 2013, there were 1.8 million new HIV infections (95% uncertainty interval 1.7 million to 2.1 
million), 29.2 million prevalent HIV cases (28.1 to 31.7) and 1.3 million HIV deaths (1.3 to 1.5). At the 
peak of the epidemic in 2005, HIV caused 1.7 million deaths (1.6 to 1.9). Concentrated epidemics in Latin 
America and Eastern Europe are substantially smaller than previously estimated.  Through interventions 
including PMTCT and ART, 19.1 million life years (16.6 to 21.5) have been saved, 70.3% in the developing 
world. From 2000 to 2011, the ratio of development assistance for health for HIV to years of life saved 
through intervention was $2,928-$4,497 in the developing world. All-forms tuberculosis (including 
individuals who are HIV-positive) incidence, prevalence and death numbers in 2013 were 7.5 million (7.4 
to 7.7), 11.9 million (11.6 to 12.2) and 1.4 million (1.3 to 1.5), the same figures in individuals who are 
HIV-negative were 7.1 million (6.9 to 7.3), 11.2 million (10.8 to 11.6) and 1.3 million (1.2 to 1.4), 
respectively. Annualized rates of change (ARC) for incidence, prevalence and death have become 
negative after 2000. Tuberculosis in HIV-negative individuals disproportionately occurs in males; 64.0% 
of cases (63.6% to 64.3%) and 64.7% of deaths (60.8% to 70.3%). Globally, malaria cases and deaths 
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grew rapidly from 1990 reaching a peak of 232 (143 to 387) million cases in 2003 and 1.2 (1.1 to 1.4) 
million deaths in 2004.  Since 2004 child deaths from malaria in sub-Saharan Africa have declined 31.5% 
(15.7% to 44.1%). Outside of Africa malaria mortality has been steadily declining since 1990. Interpretation 
Our approach produces estimates for the HIV epidemic that are 25% smaller than UNAIDS. Malaria is 
larger than estimated by WHO. HIV, tuberculosis and malaria have all declined since 2000. At the global 
level upward trends for malaria and HIV have been reversed and declines in tuberculosis have 
accelerated. 97 countries (74 developing) still have increasing HIV incidence.  Substantial progress since 
the Millennium Declaration is an encouraging sign of the impact of global action.  Funding 
Bill & Melinda Gates Foundation. 
 Introduction 
The Millennium Declaration in 2000 brought special global attention to HIV, tuberculosis and malaria 
through the formulation of Millennium Development Goal 6 (MDG 6).  The high priority status of these 
three diseases in the development community was confirmed through the creation of the Global Fund 
to Fight AIDS, Tuberculosis and Malaria in 2002.  Bilateral initiatives such as the President’s Emergency 
Plan for AIDS Relief (PEPFAR) and the President’s Malaria Initiative also added substantial new 
resources.   From 2000 to 2011, multilaterals, bilaterals, foundations and NGOs have invested $51.6, 
$11.3 and $8.3 billion 2011 US dollars of development assistance for health (DAH) for HIV, malaria and 
tuberculosis respectively.1  Substantial benefits of these investments have been documented in a 
number of studies.2–9  In the lead up to the MDG deadline of 2015 and the global debate on 
development goals post-2015, important questions have been raised about the advantages and 
disadvantages of maintaining focus on these three diseases.5,10–18   The rise of the importance of non-
communicable diseases in some regions of the developing world19–26 have led to calls for goals that 
cover a broader range of diseases.10,15,17,19,20,24,25,27,28  At the same time, ambitious goals of zero 
tuberculosis and zero HIV have been formulated by some groups;29–34 the Secretary-General of the UN 
had already established a goal of zero malaria deaths by 2015.35   Understanding the distribution and 
trends of these three diseases and how they have been influenced by the MDG era is an important input 
to this wider debate.12,36   
Because of their prominence, there are major UN efforts on an annual basis to track the epidemiology of 
these three diseases.   UNAIDS now produces country estimates of HIV incidence, prevalence, and death 
every year.37   Over many years, they have developed a sophisticated modeling approach to track the 
epidemic whose primary input in generalized epidemics is annual antenatal clinic sero-surveillance data 
and periodic household surveys that include blood testing.38,39  WHO’s annual Global Tuberculosis 
Report provides estimates of incidence and death from tuberculosis by country.  Critical inputs to the 
assessment of incidence are case notifications and national expert opinion on the case-detection rate, 
and separate modeling of cause of death data from vital registration systems and verbal autopsy (VA) 
studies.  For the World Malaria Report, WHO uses a complicated strategy to estimate incidence and 
mortality that varies by region and age-group. For child malaria deaths in Sub-Saharan Africa, the main 
inputs are verbal autopsy studies and estimated malaria risk. Estimates are adjusted post-hoc for 
Confidential draft. Please do not cite or circulate.
coverage of insecticide treated bed nets (ITNs). Outside of sub-Saharan Africa and for low-transmission 
countries in Africa reported case numbers are combined with an assumed case fatality rate. These three 
efforts have provided important insights into the geographical distribution and likely trends in the 
diseases.     
Despite these efforts, there is extraordinary uncertainty at the country level in the burden of all three.   
The burdens of HIV and malaria are concentrated in sub-Saharan Africa; countries that, outside of South 
Africa, have very poor vital registration and incomplete notification systems. Tuberculosis is 
concentrated in Asia and Southern Africa where a few more countries have better data systems but 
there are still huge gaps in information. Modeling strategies for tracking the diseases have evolved to be 
necessarily complex given the incomplete and often conflicting nature of the data. For HIV and malaria, 
UN modeling efforts explicitly use information on intervention delivery and assumed benefits of 
intervention. The distinction between data on disease outcomes and data on intervention coverage 
driving the results of these efforts is blurred.   In the more complex modeling strategies, the 
compounded impact of uncertainty about different parameters can be hard to characterize. Efforts to 
model the three diseases are largely independent of each other – the exception is recent coordinated 
efforts to understand the intersection of tuberculosis and HIV.40 
The Global Burden of Disease 2010 Study provided a comprehensive update on levels and trends of a 
large number of diseases, injuries and risk factors for 187 countries from 1990 to 2010. The Global 
Burden of Disease collaboration is now generating annual updates the first of which is the Global Burden 
of Disease Study 2013 (GBD 2013). The GBD 2013 provides an opportunity to examine the evidence on 
the levels and trends in the three MDG 6 diseases within the comprehensive and coherent framework of 
the GBD. Compared to GBD 2010, special emphasis has been given in the GBD 2013 to incorporate new 
data, more rigorously identify and incorporate further key sources of uncertainty, and incorporate 
adjustments for the biases that are present in different data sources. A critical aspect of the GBD effort 
is to quantify time trends; comparing trends from 1990 to 2000 and from 2000 to 2013 provides an 
opportunity to see if there has been accelerated progress since the Millennium Declaration.  The GBD 
2013 supersedes all previously published GBD results.   Methods 
The overall conceptual and analytical framework for the GBD is described elsewhere.41–48  Major 
refinements of the analytical approach for different diseases and risk factors are explored in other 
papers.49–51 We summarize here the methods used for the analysis of the three diseases emphasizing 
refinements since the GBD 2010. All methods refinements have been applied to the full 1990 to 2013 
time series to ensure comparability of results.  Metadata for input sources used in the GBD 2013 will be 
available in the Global Health Data Exchange upon publication of the full GBD 2013 results.  HIV 
For the GBD 2010, we primarily used estimates of prevalence and mortality developed by UNAIDS. The 
main modification was the requirement that the sum of cause-specific mortality from each cause in a 
country, age, sex and year group equaled the estimate of all-cause mortality for that country, age and 
sex group generated through the analysis of demographic sources.43  Modifications of HIV deaths 
through this internal consistency process did not lead to revisions of incidence or prevalence for HIV in a 
particular country, age, sex and year.  For the GBD 2013, we have sought to develop a set of estimates 
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of incidence, prevalence and mortality from HIV that are internally consistent with each other and also 
meet the GBD requirement that the sum of each cause of death equals all-cause mortality. Internally 
consistent means the incidence, prevalence and death figures are mathematically possible given that 
prevalence is a function of past incidence, remission and death rates for any age cohort.     Modified Spectrum Model 
UNAIDS uses two key analytical components in their epidemiological estimation.  The Estimation and 
Projections Package (EPP) is used to estimate incidence trajectories that are consistent with prevalence 
surveys and other prevalence measurements such as antenatal clinic sero-surveillance.52 Spectrum is a 
compartmental HIV progression model used to generate age-specific incidence, prevalence and death 
rates from the EPP incidence curves and assumptions about intervention scale-up and local variation in 
epidemiology.53 We have recoded Spectrum in Python, an open source higher level language that can 
easily be run on a parallelized computational cluster, following the exact structure of Spectrum to 
facilitate faster computation required for the uncertainty analysis and consistency analysis with all-cause 
mortality. We have also made four important modifications to the assumptions.     
First, we have altered the Spectrum assumptions about mortality without antiretroviral therapy (ART).  
Following UNAIDS assumptions, mortality is modeled as shown in Figure 1.   The death and progression 
rates between CD4 categories vary by age according to four age-groups, 15-24, 25-34, 35-44, and 45 and 
above. UNAIDS estimates a single set of progression and death rates by first fitting a Weibull distribution 
to data from three East African sero-converter cohorts from the ALPHA network and one miners cohort 
from South Africa,54 and then selecting a set of progression and death rates in Excel Solver that 
minimizes the sum of the squared differences between the predicted and Weibull survival 
probabilities.55,56   Uncertainty in their estimates for this component was approximated by assuming a 
coefficient of variation of 0.05 for each mortality rate. To better characterize uncertainty in the 
progression and death rates, we systematically reviewed the literature on mortality without ART. We 
searched terms related to pre-ART or ART-naive survival since seroconversion – exact search terms are 
in the web appendix. After screening, we identified 13 cohort studies which included the cohorts used 
by UNAIDS from which we extracted survival at each one year point after infection. We modeled the 
logit of the conditional probability of death between years in these studies as: 
 
Where m is conditional probability of death from year tj to t j+1, ai is an indicator variable for age group 
at seroconversion (15-24, 25-34, 35-44, and 45+), t j is an indicator variable of year since seroconversion, 
and  is a study-level random effect. By sampling the variance-covariance matrix of the regression 
coefficients and the study level random effect, we generated 1000 survival curves for each age group 
that capture the systematic variation in survival across the available studies (Figure 2 and Appendix 
Figures 1a, 1b, 1c). Across all age groups, median survival ranges from 3.6 to 29.5 years. For each of the 
1000 survival curves, we use the UNAIDS optimization framework to find a set of progression and death 
rates that minimizes the sum of the squared errors for the fit to the survival curve. For the death rates 
generated from the optimization, the coefficient of variation across the set of 1000 is 0.44-1.00 
depending on the age-group which is substantially higher than the UNAIDS assumption of 0.05. 
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Second, for mortality on ART, UNAIDS used data from five regional cohorts from the IeDEA network to 
directly estimate death rates by age, sex, and CD4 count, which have been used as the default for all 
countries in a region.57,58 Through their country consultation process some of these defaults have been 
modified. For example, Myanmar assumes a constant mortality rate by initial CD4 group, without any 
variation by age, sex, or time on treatment. To better characterize real variation in the death rates on 
ART across programs, we searched the published literature. Using the terms HIV mortality antiretroviral 
therapy, we identified 4996 titles. Screening the abstracts and papers yielded 102 total papers for 
extraction (Appendix Table 2). These included mortality and loss to follow-up (LTFU) data for 80 cohorts, 
age hazard ratios for 40 cohorts, and sex hazard ratios for 86 cohorts. We corrected reported 
probabilities of death for loss to follow-up using an update of the approach developed by Verguet et 
al.59   Verguet et al used tracing and follow-up studies to empirically estimate the relationship between 
death in LTFU and the rate of LTFU. We used DisMod-MR 2.0 to conduct a meta-regression of the data 
for on-ART mortality by initial CD4 count separately for high-income countries, GBD developing 
countries outside of sub-Saharan Africa, and sub-Saharan Africa; see Appendix section 2.3 for additional 
information. We meta-analyzed region-specific age hazard ratios using DisMod-MR 2.0, and region-
specific sex hazard ratios using the Stata command metan. The age and sex hazard ratios were applied 
to the CD4-specific mortality rates, accounting for the distribution of ages and sexes in the mortality 
data.  We used 1000 draws from the posterior distribution for each age, sex and CD4 category for 
conditional probabilities of death for 0-6 months, 7-12 months and 13-24 months after initiation of ART 
as inputs to Spectrum. Table 1 shows HIV-specific mortality rates for 25-34 year olds on ART in sub-
Saharan African; see Appendix Table 3 for HIV specific mortality for other age groups and regions. 
Third, to better reflect variation in the age-pattern of incidence, we used the UNAIDS distributions of the 
relative incidence by age prepared for UNAIDS based on selected cohort studies. To capture the 
possibility that there is greater variation across countries in the age incidence pattern than in these 
studies, we increased the uncertainty ranges by an arbitrary 50%.    
Fourth, for all other input parameters including the number of individuals receiving ART, PMTCT or co-
trimoxazole prophylaxis we randomly sampled a uniform distribution from 0.9 to 1.1 and used the draw 
to adjust each parameter. For the sex ratio of incidence, we sampled a wider but arbitrary range from 
0.8 to 1.2 reflecting the demographic data in many generalized epidemics that there is less of a 
difference between the sexes than observed in the population prevalence surveys.    Generalized Epidemics 
UNAIDS identifies 43 countries as generalized epidemics; this distinction is important because for these 
epidemics the primary sources of information on prevalence come from antenatal clinic sero-
surveillance and household surveys. In addition to these 43 countries, we have included in this category 
Senegal, Niger, and India because of the availability of population-based surveys. Prevalence data from 
countries with generalized epidemics has been analyzed by UNAIDS using EPP to generate 1000 samples 
of incidence curves for adults 15-49 consistent with the prevalence data. For each of these 1000 
incidence curves, we randomly sample the parameter distributions for all input parameters ten times to 
generate 10 000 epidemic curves of incidence, prevalence and death by age and sex. The selection of 10 
000 iterations was based on testing that it would ensure stable uncertainty intervals. Some of these 10 
000 death curves exceed in one or more age-sex-year groups the estimate of all-cause mortality based 
on demographic sources. Because the demographic estimates of all-cause mortality are based on 
substantial empirical data, these HIV epidemic curves are unlikely to represent reality. These 
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mismatches occur more often in Southern Africa.  We identify the 250 modified Spectrum curves and all-
cause mortality curves that are most consistent with each other. We define a loss function:  
 
For run r of a given country, excess mortality, e, is equal to the sum of all non-zero differences between 
HIV mortality, mHIV, and 0.8 times a randomly selected all-cause mortality draw, mall-cause, across all year-
age-sex combinations (t, a, and s respectively). We compare the Spectrum estimates to 0.8 times the all-
cause estimates because this is the highest observed fraction of deaths in any age-group in any country’s 
cause of death data due to HIV.  We randomly pair each of the 10 000 modified spectrum outputs with 
one of the 1000 all-cause mortality curves generated from the demographic analysis. The 250 pairs that 
minimize the loss function are selected.  When more than 250 have a loss function equal to zero, we 
randomly choose among this set.  We resample the 250 draws to 1000; 250 are used with resampling for 
computational convenience. Annex Figures 2a, 2b and 2c show mortality at ages 15-59 from the full set 
of 10 000 modified spectrum models and the subset that is selected through the matching process for 
Uganda, South Africa and Ghana. Demographic data matching selects in South Africa epidemic curves 
that are at the low end of the distribution with longer median survival; in Uganda this effect is slightly 
less pronounced and in Ghana pre and post matching are identical.  Concentrated Epidemics with Vital Registration Data  
UNAIDS estimates for concentrated epidemics depend critically on two inputs: first, the assessment of 
prevalence of HIV in high-risk groups (people who inject drugs, men who have sex with men (MSM), and 
female sex workers) for which there is considerable information in many countries;60–72 and second, 
assumptions on the percentage of the population in high risk groups.  Although there is guidance on 
measurement,73 real data in most countries are extremely limited. In many countries, UNAIDS estimates 
are based on local opinion.  Resulting assumptions have been highly variable across countries. For 
example, Uruguay defines 4.5% of its population as MSM while neighboring Argentina defines only 1% 
of its population as MSM. An alternative source in many countries is cause of death data from national 
vital registration systems. To track the epidemic using cause of death data can require up to three 
important adjustments.  First, in some middle-income countries, vital registration is incomplete. Wang 
et al have used death distribution methods43 to assess completeness in all countries with vital 
registration (VR); we have used this information to correct upwards incomplete registration.  Second, a 
key aspect of the GBD is to redistribute deaths that are assigned to immediate or intermediate causes of 
death rather than underlying causes of death (garbage codes).74 In addition to garbage codes, because 
HIV was not included in ICD-9 until 1986 and not implemented in many countries until later, deaths 
were often assigned to other codes such as graft versus host disease or Kaposi’s sarcoma. Third, in some 
places due to stigma or misdiagnosis, HIV deaths may be assigned to other underlying causes of death 
such as tuberculosis, endocrine disorders, meningitis or encephalitis. Birnbaum et al developed a 
method to identify these misclassified deaths.75  We applied this method to all countries. 
Misclassification of HIV deaths in the Birnbaum et al method is based on fulfilling three criteria.  First, 
the temporal trend for a cause should coincide with the HIV epidemic.  Second, the pattern of the 
relative death rate by age should shift towards the ages 15-49 during the epidemic years.  Third, the 
temporal and age-pattern shifts cannot be explained by other known epidemiological trends.  Applying 
these methods, we transfer deaths from 47 causes in 52 countries. Figure 3 shows the number of HIV 
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deaths directly coded to HIV, the number of deaths re-assigned to HIV from garbage code redistribution, 
and the number of deaths from the application of the HIV misclassification method for Thailand and 
Russia.  The height of the bar is the final number of deaths in each age-group.   
For countries with corrected vital registration, we impute missing years of data to generate a complete 
time series for HIV from the estimated start year of the epidemic using spatial-temporal Gaussian 
Process Regression (ST-GPR).43,76,77  ST-GPR using a linear mean function and a Matern covariance has 
been widely used for time-series estimation in global health descriptive studies such as for tobacco 
prevalence, obesity prevalence or child and adult mortality. To generate an internally consistent set of 
incidence, prevalence and death curves with uncertainty, we use the observed HIV death numbers to 
calibrate the modified Spectrum models. First, we start with a modified Spectrum model constructed 
based on the analysis of high-risk groups – where no high-risk group analysis is available we use a 
regional default model. Second, for each of the 1000 draws from this model, we modify the incidence at 
time t by the ratio of observed deaths to modified spectrum deaths at time t+λ, where λ is the lag 
between incidence and death. We draw from a distribution of lags of 10 to 15 years to generate 6000 
different adjusted incidence curves. For incidence for the last λ time periods, we draw a random weight 
between 0 and 1 from a uniform distribution and use it to calculate a weighted average of adjusted 
incidence in year t + λ and unadjusted incidence multiplied by the deaths ratio in year t + λ. Using these 
modified incidence curves, we rerun the modified Spectrum generating 6000 possible epidemic curves.  
As a final step, for each of these 6000 we compute the mean squared error of predicted deaths 
compared to observed deaths.  The 1000 curves with the lowest mean squared error are selected as the 
final set for analysis. Figure 4 shows the results of this process for Panama and the comparison to the 
UNAIDS high-risk group analysis; the corrected vital registration data suggests a much smaller epidemic 
with different timing.   Concentrated Epidemics with High-Risk Group Analysis and Insufficient or No Cause of Death Data 
There were 20 countries with concentrated epidemics where we had no or insufficient vital registration 
or verbal autopsy data to inform our cause of death analysis. For these countries we ran modified 
Spectrum to output 1000 draws of incidence, randomly selecting 1000 time series of the death ratios 
generated in the process described above, and multiplying each draw of incidence by the selected set of 
ratios. We selected incidence adjustments only for countries with a cumulative number of HIV deaths 
greater than 5000 to avoid exaggerated stochastic variation in the ratios. We then derived estimates of 
mortality by running the adjusted incidence curves back through Spectrum. By using random draws 
across these countries, the average correction and uncertainty in this correction is propagated into the 
corrections for these countries with limited or no data.     Concentrated Epidemics with No High-Risk Group Analysis and No Cause of Death Data 
For 13 countries (Andorra, United Arab Emirates, Iraq, Federated States of Micronesia, Libya, Marshall 
Islands, State of Palestine, Solomon Islands, Timor-Leste, Vanuatu, Samoa, Tonga, and North Korea) no 
analysis of high-risk groups has been undertaken and no cause of death data are available. For these 
countries, we picked regional or neighboring countries to approximate the death rate in these places. 
We used these approximate death rates to fit a Spectrum model.  In all these cases, the number of 
estimated deaths was less than 250 per year.   
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Comparisons to Prevalence Survey Data  
As a form of empirical validation, we compare our final estimated prevalence with national population-
based surveys collected through the Demographic and Health Surveys, AIDS Indicator Surveys, the 2005-
2006 Indian National Family Health Survey, and the 2012 South African National HIV Prevalence, 
Incidence and Behaviour Survey.78–80 In total, we extracted data from 46 surveys in 35 countries 
between 2001 and 2012. These surveys had response rates for HIV testing ranging from 63% in males in 
Malawi in 2004 to 98% for both sexes in Rwanda in 2011; median response rate was 85%. These 
comparisons are made for adults 15-49 by sex and five-year age groups. We tested for significant 
differences in means (p<0.05) for each estimate and compared the distribution of survey estimates to 
GBD and UNAIDS via OLS regression with robust standard errors to account for heteroscedasticity. HIV Intervention Counterfactual Scenario 
Spectrum uses as inputs the numbers reported by governments of individuals receiving PMTCT, co-
trimoxazole, and child and adult ART. To help understand the role of interventions including ART, 
PMTCT, and co-trimoxazole prophylaxis, we have rerun the final 1000 modified Spectrum models for 
each country using a no intervention counterfactual scenario. We turn all HIV related interventions to 
zero including ART, PMTCT and co-trimoxazole prophylaxis for all years. We compare the number of 
deaths and person-years lived each year from the base case to this counterfactual to assess the changes 
due to intervention.  Using published results on development assistance for health (DAH) for HIV, we 
compute the ratio of DAH to years of life saved.   Tuberculosis 
For the GBD 2010, we estimated tuberculosis mortality and then estimated population incidence 
through mixed effects regression as a function of tuberculosis mortality, case-notifications and an 
indicator variable for health system access used as a proxy for completeness of registration. For GBD 
2013, we have shifted to using all available data on different outcomes and simultaneously estimating 
incidence, remission, excess mortality, prevalence and cause-specific mortality using the GBD Bayesian 
meta-regression environment, DisMod-MR 2.0 (appendix section 2.4). There are four potential sources 
of information to estimate national levels and trends for tuberculosis in a country: annual case 
notifications, expert judgment on the case-detection rate, prevalence surveys and cause of death data.  
In addition, to facilitate convergence of the meta-regression, estimated excess mortality and remission 
rates have been used. The approach is predicated on the principle that incidence, prevalence and 
mortality may be measured imperfectly and that a statistical triangulation of all the sources for a 
country will provide a more robust assessment. Our meta-regression analysis was conducted for all 
forms of tuberculosis. As a final step we estimated incidence, prevalence and death in individuals who 
are HIV-positive and those who are HIV-negative. We explain in more detail the preparation of each of 
these sources.   Adjusted Case Notifications and Incidence   
Case definitions for tuberculosis since 1995 have been standardized by WHO and widely applied. 
Countries have varied however in the completeness of reporting for younger age-groups and some 
countries have reported only pulmonary smear-positive cases for selected years. We use the age and 
sex-specific notifications in our analysis and impute the missing age-groups for three forms of 
tuberculosis notifications (pulmonary smear-positive, pulmonary smear-negative, or extra-pulmonary) 
in two steps. First, for each country-sex category with missing age-groups in some years, we imputed the 
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missing values by regressing the log of the case notification rate on dummy variables for 5-year age-
groups and random effects on year using all the data observed in a country over the interval 1990 to 
2013.       
Second, we estimated the relationships between all forms of tuberculosis and smear-positive 
tuberculosis and the relationship between all forms and bacteriologically positive tuberculosis. Using 
country-years with complete notifications (all three forms), we used a compositional analysis model to 
simultaneously estimate the fraction of cases due to all three forms as a function of dummy variables for 
five-year age-groups and sex and the smear-positive tuberculosis rate. This regression was used to 
impute missing values for pulmonary smear-negative and extra-pulmonary cases. Because of marked 
variation in the diagnostic rates for extrapulmonary tuberculosis and the potential for misclassification, 
we used the predicted values for extrapulmonary cases for all countries from the regression.  
At the country-level a number of smear-unknown and relapsed cases are recorded that are not captured 
in the age and sex-specific notifications.  We use the relationship between these forms and pulmonary 
smear-positive cases in the country-level data to inflate the adjusted age and sex-specific pulmonary 
smear-positive notifications used in our analysis. Case notifications, however, do not capture all true 
incidence cases in the population. Case notifications can be incomplete because some cases are not 
diagnosed and some diagnosed cases are not reported to the national tuberculosis program.  
Population-based incidence studies for tuberculosis based on active surveillance are rare and have not 
been conducted at the national level. 81 In the absence of direct measurement of true incidence, the 
case detection rate must be approximated.  Since 2008 the WHO has been consulting with national 
tuberculosis program managers in 96 countries to collect expert opinion on the case detection rate 
including some notion of subjective uncertainty.82 For the remaining countries, case-detection estimates 
are based on the judgment of WHO staff. We divided adjusted case notifications by the estimated case 
detection rate to generate the incidence inputs used for DisMod-MR 2.0. We expanded the subjective 
uncertainty intervals reported so they are at a minimum plus or minus 20% from the estimated values or 
for values less than 20% we assume the standard error is half the midpoint estimate. Tuberculosis Prevalence Surveys 
Prevalence surveys have been periodically undertaken in a limited number of countries.  WHO has 
standardized the protocol83 and the Global Fund to fight AIDS Tuberculosis and Malaria (GFATM )has 
funded a recent round of surveys of which 16 are completed or ongoing and 10 more are planned .84  
Because the prevalence rates for tuberculosis are often comparatively low, e.g. 200 per 100 000, 
prevalence surveys need to be large to provide breakdowns by age and sex. Based on the literature and 
country reports, we have identified 27 national and 24 subnational prevalence surveys in 24 countries 
spanning the time period 1985 to 2013. We have included in our analysis, surveys reporting on 
pulmonary smear-positive tuberculosis and bacteriologically positive tuberculosis. We included in the 
Bayesian meta-regression study level dummy variables for the different measured outcomes with the 
reference category being bacteriologically positive. We allowed for non-sampling variance for sub-
national surveys to be larger which effectively down-weighted their importance for the estimation in a 
given country. Because mortality and incidence data are for all forms of tuberculosis, we adjusted 
prevalence surveys to account for extra-pulmonary cases using the same factors used in the adjustment 
of case notification data.  
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Tuberculosis Mortality 
We used 2731 country-years of nationally representative vital registration data and 166 site-years of 
verbal autopsy data to estimate tuberculosis mortality. Vital registration data were adjusted for garbage 
coding following GBD algorithms74,85 and misclassified HIV deaths described above.  Deaths by age and 
sex for tuberculosis were modeled using the Cause of Death Ensemble modeling (CODEm) approach.76  
CODEm has been extensively used in global cause of death analyses.74  Using CODEm we test a very wide 
range of potential models and use out of sample predictive validity to select the best individual models 
and the best ensemble of these models.  Appendix Tables 5, 6a and 6b provide details on the application 
of CODEm to tuberculosis. CODEm was run separately for males and females. The final ensemble models 
selected had a root-mean squared error of the log of the age-specific death rate of 0.29 in-sample and 
0.63 out-of-sample for males and 0.70 in-sample and 1.05 out-of-sample for females. In the out-of-
sample predictive validity testing (cross-validation), the coverage of the 95% data prediction uncertainty 
interval was 93% and 91% for males and females, respectively.   
CODEm results are largely informed by ICD coded data which by definition exclude tuberculosis 
mortality in HIV positives. The overall Bayesian model, however, is for all forms of tuberculosis in HIV 
negatives and positives because prevalence data rarely distinguish HIV status. We estimated the fraction 
of HIV deaths due to TB-HIV and added these to tuberculosis mortality in HIV negatives. The model for 
the fraction of TB-HIV mortality was based on 1022 country-years of data where cause of death data for 
TB-HIV and HIV overall were available. We estimated the relationship between the logit-transformed 
fraction of HIV deaths due to TB-HIV and the log-transformed tuberculosis death rate, a dummy variable 
for sex, year and country random effects. This regression was used to predict the fraction of HIV deaths 
due to HIV-TB in all countries.  Remission and Excess Mortality Estimates 
To help inform the model, we generated a prior for remission by examining the ratio of incidence to 
prevalence in the country-years where prevalence surveys have been undertaken. We used a simple 
regression with random effects to generate priors for countries with surveys and those without. Cause-
specific mortality estimates inform estimates of prevalence through excess mortality in DisMod-MR 2.0. 
To provide the model with the range of age- and sex-specific excess mortality hazards associated with 
tuberculosis we analyzed historical data where we had both tuberculosis mortality data and incidence 
data that were believed to be nearly complete. For this analysis, we used the WHO case notifications 
from 1980 onwards with the supplement of age-sex-specific case notifications back to the 1950s for 
Australia, Canada, United Kingdom, United States, Japan, and Germany. Case notification data were 
combined with tuberculosis deaths recorded in the vital registration systems to generate 743 country-
year observations from 70 countries that could be used to inform our analysis. We estimated the 
relationship between incidence and mortality for each sex, by regressing the logit-transformed ratio of 
incidence to mortality against age, lag-distributed income per capita and country random effects. The 
addition of HIV prevalence off-ART to the regression gave inconsistent coefficients between females and 
males and was not included in the final model. We estimated the relationship between incidence and 
prevalence as a function of lag-distributed income per capita with country random effects.  Predicted 
death to incidence ratios and incidence to prevalence ratios were transformed into estimates of excess 
mortality and remission using the mathematical relationships between them (see Appendix section 2.2 
for additional information).   
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DisMod-MR 2.0 
For each country we included in the DisMod-MR 2.0 estimation the adjusted case notifications, 
prevalence survey data if available, estimated excess mortality hazard by age and sex, estimated 
remission and the TB-HIV adjusted cause-specific mortality estimates from our CODEm model. DisMod-
MR 2.0 provides internally consistent estimates for 1990, 1995, 2000, 2005, 2010 and 2013 for 188 
countries of incidence, remission, excess mortality, prevalence and cause-specific mortality using all 
forms of data or priors in the estimation. Figure 5 illustrates the internally consistent fit for Kenya in 
2013.  For intervening years, we interpolated rates.      Estimating Tuberculosis Incidence, Prevalence and Death in Individuals who are HIV-positive 
Tuberculosis all forms estimates coming from DisMod-MR 2.0 were used to estimate incidence and 
prevalence in HIV positives using a relative risk (RR) approach. We reviewed the literature using the 
search terms incidence risk ratio HIV tuberculosis antiretroviral therapy and used meta-regression to 
estimate a RR of tuberculosis incidence in HIV positive individuals in the absence of ARTs based on 7 
studies86–92 of 8.7 (5.9 to 11.7).  Studies show that the RR of tuberculosis incidence is a function of CD4 
count and ART; to parse out the increasing risk ratios of tuberculosis by decreasing CD4 count and the 
decreasing risk ratio on ART we relied on data from the Badri et al93 study.  The RRs we calculated from 
this analysis are 15.7 (10.6 to 21.1), 10.8 (7.3 to 14.5), 3.2 (2.2 to 4.3), and 1.7 (1.2 to 2.3) for the <200, 
200-350, and >350 CD4 count categories and the ART category. We computed population attributable 
fractions (PAFs) for each category using the outputs of Spectrum above.  For prevalence we assumed, 
that each category of incident tuberculosis cases in HIV positives has the same duration. TB-HIV 
mortality was estimated as described above.   Malaria 
Murray et al developed estimates of mortality and incidence for malaria for the GBD 2010.74,94 They 
estimated malaria mortality using vital registration and verbal autopsy data analyzed using CODEm.  
Published community incidence studies were meta-analyzed to generate a model of incidence as a 
function of mortality, age, sex and region. We have modified this method for the GBD 2013 update.  
Considerable debate emerged since the publication of that analysis on the validity of verbal autopsy 
(VA) for adult malaria deaths.95–100 For the GBD 2013, we undertook a systematic review of the literature 
on the validity of VA for malaria. Our inclusion criteria were validation studies that used physician-
certified verbal autopsies, reported both sensitivity and specificity for malaria, and had hospital 
diagnosis as the gold standard. However, the quality of the gold standards used in these studies is 
variable, and in some of them malaria cases were not confirmed with a blood smear and/or did not use 
a case definition with a threshold of parasitemia. We identified seven studies.101–107 We first tested in a 
meta-regression if there was any significant difference between studies with and without parasitemia 
confirmation and found none.  We meta-analyzed these studies to estimate sensitivity and specificity, 
separately for children and adults. Forest plots for adult and children are shown in Figure 6a and 6b, 
respectively.  We have as a sensitivity analysis undertaken to use this correction but it leads to 
substantially larger numbers of estimated deaths in adults from malaria – see Appendix Figure 3 for 
details.  We have chosen not to correct the data for the main results of this paper because it would 
adjust deaths in adults upwards which is contrary to expert opinion in the literature.   
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Given that we have not applied the sensitivity and specificity corrections, we have instead modified the 
redistribution of garbage codes such as fever of unknown origin or ill-defined deaths, so that we do not 
redistribute garbage codes to malaria in adults. We have also updated all the times-series covariates 
tested in the models: rainfall, health-system access, antimalarial drug resistance weighted by drug use, 
ITN coverage, indoor residual spraying coverage, income per head and educational attainment. We have 
also included in the model the 2010 Plasmodium falciparum parasite rate (PfPR) map from the Malaria 
Atlas Project.108  A coherent analysis of PfPR overtime is underway but was not available for this analysis. 
Appendix Table 14 provides details on the CODEm model analysis. As in the Murray et al study, we 
developed separate models for sub-Saharan Africa and outside of Africa (with the exception of South 
Africa, which was modelled with countries outside of Africa, given the low malaria endemicity), age 
under 5 years and 5 years or higher, and males and females.  
For countries that have only or mainly Plasmodium vivax transmission we used the number of deaths by 
year and age from vital registration data as a simple predictor of malaria mortality using a negative 
binomial regression model. 
Malaria cases were estimated separately for three sets of countries, which were divided based on the 
availability and quality of malaria incidence data – see Appendix Table 15 for the list of countries. The 
first group contained countries with unavailable or unreliable malaria case reporting systems. We 
estimated malaria incidence in these countries using a mortality-incidence model, in which we predicted 
malaria incidence by regressing the log-transformed study-level incidence on the log-transformed 
malaria mortality rate, age-group indicators, a sub-Saharan Africa indicator, an indicator distinguishing 
active vs. passive case detection (set to active when generating predictions), and the ratio of the site-
specific PfPR to national PfPR (from MAP 2010; set to the value “1” when generating predictions so that 
the estimates are nationally representative).  In this model the incidence data came from studies 
published in the literature and the mortality data came from our CODEm analysis. The second group 
included countries for which there were incomplete administrative data, for which we predicted malaria 
incidence by regressing incidence data from the World Malaria Report 2013 on national-level PfPR. We 
corrected for underreporting using a composite indicator for health system access as a proxy. The third 
group contained countries with complete and reliable administrative case reports, for which we used 
reported numbers as published in the World Malaria Report.  CodCorrect Algorthm 
As with all causes of death analyzed for the GBD, we require that the sum of each individual cause of 
death for a country, age, sex, year equals the estimate of all-cause mortality. The CodCorrect algorithm 
rescales the sum of causes at the individual draw level. The effect of this simple algorithm is to change 
causes that have larger uncertainty intervals if there is a mismatch between the sum of cause-specific 
mortality and all-cause mortality. In order to preserve the relationships between incidence, prevalence 
and death that come from the Spectrum analysis, the entire epidemic curve for HIV is scaled in 
CodCorrect.   Role of the funding source 
The sponsor of the study had no role in study design, data collection, data analysis, data interpretation, 
or writing of the report.  The authors had access to the data in the study and the final responsibility to 
submit the paper. 
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Results HIV 
Figures 7a, 7b and 7c show the estimated trend in global numbers of incident cases, people living with 
HIV (prevalence) and deaths from HIV.  UNAIDS estimates are shown for comparison. Global HIV 
incidence peaked in 1997 with 2.8 million (2.7 to 3.1) new infections and has declined since the peak at 
2.7% (2.0% to 3.1%) per year. From 1997 to 2005, incidence declined at 3.8% (3.0% to 4.6%) per year 
and from 2005 to 2013 at 1.6% (0.6% to 2.4%) per year.  New infections in children declined from 340 
thousand (323 to 363) in 2000 to 134 thousand (123 to 152) in 2013 at an annualized rate of change 
(ARC) of -7.2% (-7.8% to -6.4%), while new infections in adults declined from 2.3 million (2.1 to 2.4) to 
1.7 million (1.6 to 2.0), falling at 2.4% (1.6% to 3.0%) per year, on average, over this period. Annual 
incidence estimated by UNAIDS is uniformly higher in the years shown and shows a sharper rate of 
decline.  Prevalence of individuals infected with HIV has steadily risen to 29.2 million (28.1 to 31.7) in 
2013 rising more rapidly from 1990 until about 2000 at an annual rate of change of 10.6% (10.1% to 
11.3%) , increasing at 1.2% (0.9% to 1.4%) per year since then (Figure 7b). Compared to UNAIDS, we find 
in 2012, 6.6 million fewer individuals living with HIV. 32.0% of this difference is in sub-Saharan Africa and 
68.0% is elsewhere.  Figure 7c shows a substantially different trend for HIV deaths compared to UNAIDS, 
with a peak mortality of 1.7 million (1.6 to 1.9) in 2005. Annual mortality has subsequently fallen to 1.3 
million (1.3 to 1.5) in 2013, an ARC of -3.1% (-4.0% to 2.2%). As for incidence and prevalence, while the 
time trend of mortality estimated by UNAIDS is similar to ours, the estimated number of deaths is 
substantially greater. At the peak of the epidemic in 2005, our revised assessment of the HIV epidemic 
suggests 635 thousand fewer deaths  than UNAIDS although the difference (240 thousand) had 
narrowed considerably by 2012, the last year available from UNAIDS.  For the interval 2005 to 2012, the 
UNAIDS ARC for death numbers was -5.0% (-5.6% to -4.5%) reflecting the lower assumed death rates on 
ART in the UNAIDS version of Spectrum.  
New HIV infections are concentrated in young adults and to a much lesser extent, in children under 5, as 
shown in Figure 8a; 4.1% (3.8% to 4.5%) of new infections occur over age 60.  New cases in 2013 
occurred equally in males and females. However, there are more infections in women compared to men 
at ages 15-24 years. Incidence in children, as well as older adults, is similar for males and females.  
Reflecting a mean survival time of more than 10 years in most countries and age-groups, the age pattern 
of deaths peaks in women at ages 30-34 years and in men at a 10 years older age group (Figure 8b).  
More (53.9% [51.9% to 56.1%]) deaths are in males than in women and girls. A larger share, 6.8% (6.2% 
to 7.4%), of deaths occur beyond age 60 compared to incident cases (4.1% [3.8% to 4.5%]).    
Table 2 quantifies the ARCs for 1990-2000 and 2000-2013 for incidence, prevalence and death for the 21 
GBD regions and the world. ARCs between two fixed time periods need to be interpreted bearing in 
mind that measures of the HIV epidemic such as incidence and death will have peaked and declined in 
particular countries at different times during the interval. Nevertheless, the table clearly shows the 
accelerated progress in most of the world’s regions. The only regions with a reversal in the ARC such 
that incidence was declining but in the later period is increasing or stagnating are  Southeast Asia, North 
America High Income, Western Europe, Australasia and Tropical Latin America. The former is explained 
by the large decline in the 1990s achieved by a successful campaign to reduce infection through 
commercial sex encounters in Thailand, the country in the region with the largest epidemic. The reversal 
of incidence trend in North America may reflect a wearing off of the effect of public health measures to 
reduce the risk of transmission in MSM populations. The only regions with an ongoing increase in 
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mortality in the 2000-2013 period are East Asia, Eastern and Central Europe and North Africa Middle 
East.   
Age-standardized HIV incidence rates (Figure 9a) in 2013 ranged from below 0.7 per 100 000 in a group 
of countries ringing the Eastern Mediterranean , parts of northern and central Europe, as well as 
Mongolia to more than 550 per 100 000 in  South Africa, Lesotho and Swaziland. HIV infection follows 
distinct geographic patterns with continued high levels of infection throughout Eastern and Southern 
Africa, with some exceptions. Rwanda, Burundi, Democratic Republic of the Congo (DRC), Congo and 
Gabon all have incidence rates less than 120 per 100 000, lower than their neighbors. Incidence rates 
vary widely in sub-Saharan Africa, but are more homogenous across countries in Asia as well as North 
and South America. Important exceptions to these patterns include incidence rates above 16 per 100 
000 in many Caribbean countries. Incidence rates are notably higher in Portugal and the Ukraine, as well 
as Russia and some Central Asia republics. Figure 9b shows prevalence rates in countries in 2013. 
Geographical patterns are similar to incidence, although some differences are noteworthy.  Prevalence 
levels are highest in Botswana, Lesotho and Swaziland (above 12 000 per 100 000 population). As for 
incidence, there is substantial variation within sub-Saharan Africa; prevalence rates in Botswana, for 
example, are 16 times higher than in the DRC and 41 times higher than Niger. In Southeast Asia, 
prevalence is substantially higher in Thailand and Papua New Guinea. Prevalence rates are 
comparatively high in parts of Europe and Central Asia (Portugal, Spain, Ukraine, Russia and Kazakhstan) 
and in Latin America and the Caribbean (Panama, Honduras, Belize, Guatemala, Guyana, Suriname, 
Haiti, Dominican Republic, Jamaica and Bahamas) where prevalence levels exceed 220 per 100 000.   
Comparison of Figure 9a and 9b highlights some differences for countries in their comparative ranking 
for incidence and prevalence such as for Sweden and Australia.  Cross-national variations in HIV 
mortality rates, shown in Figures 9c, largely mirror the pattern reported for prevalence, varying from 
less than 0.2 per 100 000 in northern and central Europe and the Eastern Mediterranean, to more than 
510 per 100 000 in Southern Africa, a roughly 2500 fold difference.  More detail on the estimated 
number of new infections and deaths in 2013 for males and females and for both sexes combined for 
188 countries, along with ARCs in age-standardized incidence and death rates for both sexes combined, 
is given in Table 3. 
By comparing the estimated number of person-years lived in a no intervention scenario with actual 
estimates, we can compute the years of life saved through ART, PMTCT and co-trimoxazole prophylaxis.  
Figure 10 shows cumulative years of life saved by GBD Region as a result of these interventions during 
three phases of scale-up. From 1990 to 2003, 1.5 million years of life (1.2 to 1.9) were saved, of which 
only 22.7% (14.2% to 32.1%) were in populations living in the developing world largely in Brazil.  The 
number of years of life gained increased dramatically in the period 2004 to 2008 to 3.9 million (3.2 to 
4.7), and the share in populations in the developing world increased to 52.6% (44.1% to 62.2%). 
Between 2009 and 2013, the number of life-years gained was 13.7 million (11.8 to 15.7). More 
importantly, a much greater share (40.8% [33.8%-47.6%]) of these life years saved were in Eastern and 
Southern Sub-Saharan Africa, and a further 12.1% (9.0-15.7) in Western Sub-Saharan Africa. Other 
regions to benefit substantially from HIV interventions include High-Income North America, Western 
Europe and South Asia. The number of years of live saved continues to grow rapidly due both to the 
continued expansion of ART as well as the cumulative impact of infections prevented in children. By 
2013, the global cumulative number of years of life gained was 19.1 million (16.6 to 21.5); 14.2% (12.4% 
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to 16.2%) under age 15, 49.7% (45.8% to 53.4%) in 15-49 year olds, and 36.1% (32.7% to 39.5%) over age 
50.    
Since 2000, cumulatively DAH for HIV up through 2011 totals $51.6 billion dollars for HIV of which $33.6 
billion can be traced to specific country programs in 2011 US dollars.109 Comparing the total invested in 
HIV prevention and treatment to the years of life saved 2000 to 2011 yields in developing countries a 
ratio between $2928 to $4497 per life-year saved depending on which total figure you use. Of note, the 
ratio of DAH for HIV to years of life saved varies widely from $2.38 in Uruguay per life-year saved to 
$1.87 million in Mongolia per life-year saved.  
The scale-up of ART has been variable across countries. Because of the temporal dynamics of the 
epidemic in different countries, comparisons of intervention scale-up are confounded by the timing of 
incidence. Nevertheless, Annex Figure 4 shows a crude comparison of years of life saved over the age of 
15 divided by prevalent cases over 15 in 2013. This ratio ranges from less than 0.05 in countries with 
minimal intervention to over 0.45 in most high-income countries. In developing countries, Brazil stands 
out with a ratio of 0.41.  In the next tier, with ratios between 0.3 and 0.4 includes many countries in 
Latin America, Botswana, Namibia, Thailand, Cambodia, South Korea, and selected countries in Central 
Europe. In Eastern and Southern Africa, Mozambique, Ethiopia, Rwanda and Burundi have higher ratios 
than many neighbors. Marked variation within regions points to the historical variation in the timing of 
the epidemic response.    
Figure 11 shows a comparison of our estimated prevalence for country-age-sex groups against national 
population prevalence surveys. For comparison, the figure shows UNAIDS estimated prevalence as well. 
This comparison provides a rough check that at the end of the modeling process our assessment 
remains consistent with population-based prevalence measurements as well as being consistent with 
data on all-cause mortality. In general, there is a strong correlation (0.96) of our country-age-sex 
estimates with survey prevalence – UNAIDS prevalence is also correlated 0.96 with survey data.  
However, in 21% of cases, there is a statistically significant difference (19% for UNAIDS). The coefficients 
obtained by regressing both GBD and UNAIDS estimates on survey estimates showed that both methods 
tended to be slightly higher than the surveys; however, only the UNAIDS coefficient was statistically 
significantly larger than one – UNAIDS: 1.08 (1.03 to 1.13), GBD: 1.02 (0.98 to 1.06).  Country-specific 
graphs comparing GBD, UNAIDS and survey prevalences by age and sex are provided in Appendix Figure 
6.  Tuberculosis 
Figure 12 shows the evolution of tuberculosis incident case numbers, the number of prevalent cases and 
the number of deaths from 1990 to 2013. Total tuberculosis numbers are shown as well as numbers for 
tuberculosis in individuals who are HIV-negative – WHO estimates are included for comparison. The 
number of incident cases for tuberculosis in individuals who are HIV-negative has increased from 5.0 
million (4.8 to 5.1) in 1990 to 7.1 million (6.9 to 7.3) in 2013, a 1.5% (1.4% to 1.6%) annual change.  
Prevalence in 1990 and 2013 was 1.6 times higher than incidence implying a duration of 20 months on 
average for a case. Prevalence rates rose slightly between 1990 and 2000 (ARC 0.4%, 0.2% to 0.6%) but 
declined by 1.3% (1.4% to 1.2%) per year from 2000 to 2013. Deaths from tuberculosis in individuals 
who are HIV-negative are declining at a faster rate from 1.8 million (1.7 to 1.9) in 1990 to 1.3 million (1.2 
to 1.4) in 2013, a -1.4% (-1.9% to -1.0%) annual change. Declining death numbers and rising incidence 
numbers implies that the case-fatality rate has been declining over the period; the ratio of deaths to 
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incidence overall went from 0.36 (0.33 to 0.39) in 1990 to 0.18 (0.16 to 0.20) in 2013, a -2.9% (-3.4% to -
2.5%) per year rate of change. The majority of global tuberculosis incidence cases and deaths in 
individuals who are HIV-negative are in men and boys, 64.0% (63.6% to 64.3%) incidence and 64.7% 
(60.8% to 70.3%) mortality (Figure 13). Although age-specific rates rise with age up to age 70, given the 
comparatively young age-structure of countries with substantial burden of tuberculosis in individuals 
who are HIV-negative, 83.2% (82.6% to 83.8%) of cases and 58.8% (56.7% to 60.6%) of deaths are under 
age 60 in 2013.   
Table 4 provides a summary at the global and regional level of the ARCs for age-standardized rates of 
incidence, prevalence and death for tuberculosis in individuals who are HIV-negative (see Appendix 
Table 10 for tuberculosis including HIV-positives). At the global level, age-standardized mortality rates 
declined by 3.3% (4.1% to 2.6%), while incidence remained stable (0.0%, -0.2% to 0.2%) and prevalence 
rates increased by 0.4% (0.2% to 0.6%) during the period 1990 to 2000. Global declines continued in the 
period 2000 to 2013 for mortality, -3.7% (-4.4% to -3.0%) while incidence and prevalence started 
declining by 0.6% (0.7% to 0.5%) and 1.3% (1.4% to 1.2%), respectively. Across regions, in the period 
2000 to 2013, incidence rate ARCs in individuals who are HIV-negative ranged from 0.9% (0.7% to 1.1%) 
in Oceania to -3.3% (-3.1% to -3.6%) in high-income North America.   Twelve of 21 regions had a greater 
decline in the incidence rate from 2000 to 2013 than for 1990 to 2000. Mortality rate declines in 
individuals who are HIV-negative were greater in the period 2000 to 2013 than the declines in 
prevalence in all 21 regions. The global decline in prevalence from 2000 to 2013 is largely accounted for 
by the large declines in just two regions: East and South Asia. In South Asia, which accounts for 34.8% 
(33.9% to 35.6%) of incident cases and 47.7% (43.5% to 51.8%) of deaths in 2013, the ARCs for 2000 to 
2013 were -1.1% (-1.3% to -0.8%), -2.4% (-2.7% to -2.2%) and -4.2% (-5.6% to -2.9%) for incidence, 
prevalence and mortality rates respectively. Accelerated declines in prevalence, incidence and mortality 
occurred in East Asia from 2000 to 2013; -3.2% (-3.4% to -2.9%) for prevalence, -2.1% (-2.4% to -1.9%) 
for incidence and -7.5% (-8.5% to -6.6%) for mortality. The tuberculosis trend in Eastern Europe has 
turned around; in the 1990s mortality, incidence and prevalence rates were all on the rise, ARCs of 5.5% 
(0.6% to 6.5%), 1.3% (1.0% to 1.7%) and 1.7% (1.4% to 2.0%), respectively. However, in the period 2000 
to 2013 the trends for all there of these indicator have improved, ARCs -5.0% (-5.8% to -4.0%), -0.6% (-
0.8% to -0.4%) and -0.7% (-1.0% to -0.5%).  Table 5 shows incidence numbers and death numbers by 
country in 2013 along with ARCs for age-standardized rates. 
Figures 14a and 14b show maps of age-standardized incidence rates and death rates for tuberculosis in 
individuals who are HIV-negative in 2013. Age-standardized incidence of tuberculosis in individuals who 
are HIV-negative is over 200 per 100 000 in 24 countries in sub-Saharan Africa as well as North Korea, 
Timor-Leste, Cambodia, Laos, Philippines and Kiribati (Figure 14a). There are an additional 16 countries 
with rates over 150 per 100,000 that include Bangladesh, Myanmar, India, Pakistan, Ethiopia and 
Malawi. Figure 14b shows tuberculosis death rates in individuals who are HIV-negative which are above 
10 per 100 000 in all countries in sub-Saharan Africa and reach to levels over 50 per 100 000 in 
40countries. Among middle-income countries outside of sub-Saharan Africa, Afghanistan, Indonesia, 
India, Myanmar, and the Philippines stand out as countries with death rates over 50 per 100 000. The 
highest age-standardized death rates in Latin America and the Caribbean are in Haiti followed by Bolivia 
and Peru. Death rates are highly variable in North Africa and the Middle-East ranging from very low 
rates in Syria and Jordan to higher rates in Morocco and Yemen with 0.5 (0.3 to 0.9), 0.8 (0.6 to 1.0), 
14.3 (11.2 to 17.5), and 19.9 (11.5 to 41.5) per 100 000 respectively in 2013. Eastern Europe and Central 
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Asia stand out with death rates that are dramatically higher than Western or Central Europe. China has 
lower rates of death than Eastern Europe and Central Asia. Our findings are reasonably consistent with 
the list of high-burden countries used by WHO; however, our top 22 countries in terms of case numbers 
or death numbers that are not on the WHO high-burden list include South Korea, North Korea, and 
Madagascar for case numbers and Angola and Zambia for mortality. WHO high-burden countries that 
did not make our top 22 list for case numbers include Afghanistan, Cambodia, and Tanzania, while the 
WHO high-burden countries that did not make our top 22 list for mortality include Brazil and Cambodia.  Malaria  
Trends in the annual number of new cases of malaria, and annual deaths from malaria, are shown in 
Figure 15a and 15b, respectively for the period since 1990. For comparison, the estimates contained in 
the World Malaria Report 2013 are shown for a somewhat shorter period. Global incidence appears to 
have peaked in 2003 at 232 million cases (143 to 387) and has since fallen by about 29% to 165 million 
new cases (95 to 284) in 2013. What is clear is that there is massive uncertainty around these estimates; 
the 2013 estimate, for example, could be anywhere between 95 million and 284 million. The estimates 
of new malaria cases in the World Malaria Report fall within the uncertainty intervals of the GBD 
estimates with a mean number of new cases in 2012 of 207 million (135 to 287). In contrast, the World 
Malaria Report estimates of malaria deaths are somewhat lower (Figure 15b). There are also some 
important differences in the timing of the peak and decline in malaria mortality. Annual malaria deaths 
began to decline from a peak of 1.2 million (1.1 to 1.4) in 2004 to about 855 thousand (703 to 1032) in 
2013, having increased from 888 thousand (793 to 993) in 1990. According to the World Malaria 
Report,110 malaria caused about 627 thousand deaths in 2012, having reached a peak of about 900 
thousand around the turn of the century. The age-sex pattern of global malaria incident cases and 
deaths in 2013 is shown in Figure 16a and 16b, respectively. The largest number of cases is in the age 
groups under 15. Malaria deaths, in contrast, are concentrated at ages under 5 years although malaria 
caused between 10 and 25 thousand deaths in each 5 year age group beyond age 15, so that the 
cumulative fraction of malaria deaths in adults reaches 33.75%.  
Globally age-standardized malaria incidence and death rates were increasing in the period 1990 to 2000 
(Table 6), but many regions outside of sub-Saharan Africa and North Africa and the Middle-East saw 
declines in age-standardized incidence and/or death rates. In the period since 2000, the vast majority of 
regions including in sub-Saharan Africa saw declines in age-standardized incidence and death rates. 
Incidence declined 38% (37% - 40%) in Central Asia since 2000, which relates to increased elimination 
efforts in the region. Figure 17A shows the distribution of the age-standardized incidence rate in 2013. 
The geographic distribution of the age-standardized mortality rate (Figure 17B) shows a similar pattern 
with the highest rates in Mozambique, Burkina Faso, Guinea-Bissau, Mali, Sierra Leone, The Gambia and 
Guinea.  Rwanda stands out as having comparatively low rates compared to its neighbors. Outside of 
Africa, Yemen, India, Myanmar and Papua New Guinea have death rates over 8.5 per 100 000.  In 
Southeast Asia, Thailand and Malaysia have achieved very low death rates. Table 7 shows incidence 
numbers and death numbers by country in 2013 along with ARCs for age-standardized rates. Four 
countries have over 5 million cases a year including India with over 61 million cases, Nigeria (with 30), 
Democratic Republic of the Congo (6), and Mozambique (6). Three countries - Nigeria, DRC, and India - 
account for roughly 50% of all malaria deaths in 2013.   
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Discussion 
HIV, tuberculosis, and malaria remain major health challenges in 2013 causing 1.3 (1.3 to 1.5), 1.3 (1.2 to 
1.4) and 0.9 (0.7 to 1.0) million deaths respectively. The mean age of death differs substantially between 
them, 15.3 years (12.7 to 18.3) for malaria, 38.6 years (38.1 to 39.2) for HIV and 52.9 years (52.1 to 53.9) 
for tuberculosis in HIV-negatives which means that the burden in terms of years of life lost varies across 
the diseases. Tuberculosis death declined globally since 1990 and after 2000 incidence, prevalence and 
death have declined. HIV incidence peaked in 1997 and mortality in 2005 with substantial declines since 
the peak in each. Malaria incidence and mortality peaked and began declining in 2004 with substantial 
drops in child deaths in sub-Saharan Africa over the last 5 years. There is marked variation both in levels 
and trends for all three diseases across countries.  Notably HIV and malaria incidence and death are 
concentrated in sub-Saharan Africa while tuberculosis burden is more widespread but most pronounced 
in South and Southeast Asia.   
A notable finding from our analysis of HIV data is that the HIV epidemic is smaller than estimated by 
UNAIDS. Our global epidemic curve for mortality ranges was lower than estimated by UNAIDS for every 
year, at the peak in 2005 our estimates are 27.0 % lower and 14.5% lower in 2012. Our estimates of 
global prevalence differ by 17.1% in 2005 and 18.7% in 2012. The substantial differences in the number 
of deaths stem from two key differences in our analysis compared to that conducted by UNAIDS. First, in 
the 125 concentrated epidemics with some cause of death data on mortality due to HIV, our estimated 
mortality is 52.2% lower in 2000 and 58.4% lower in 2012. Our prevalence estimates for example for 
Panama, Colombia, or Russia are 36.3%, 52.2% and 58.4% lower, respectively. Second, in the large 
generalized epidemics, selecting epidemic curves that are consistent with prevalence data, all-cause 
mortality, and published studies on survival with and without ART shifted median survival up. For 
example, in Southern Africa, median survival off-ART for the age-group 25-34 was shifted from 10.5 to 
11.5 years.  Longer or shorter survival off-ART in some countries could be explained by genetic 
factors,111–115 co-factors such as the presence of other diseases like malaria,116–118 differential access to 
treatments for opportunistic infections or other co-factors that have yet to be described.  These findings 
are important in terms of identifying the magnitude and comparative burden of HIV.   
Comparison of population-based surveys with our estimates of prevalence suggest reasonable 
alignment and the regression analysis of estimated prevalence on measured prevalence suggest there is 
not systematic tendency in our estimates to over or under-estimate prevalence. However, there is still 
considerable variation by age and sex with nearly one in five of our age-sex specific prevalence 
estimates statistically different than the survey prevalences. There are a number of potential 
explanations. Our assumptions on the relative incidence pattern by country may not reflect local reality.  
Differential non-response in the surveys by age and sex is also a potential factor. The adjustments made 
in through the demographic matching and CodCorrect algorithm may contribute to the differences. 
More analysis on a country by country basis will be helpful in exploring these issues in future research.  
Revisions of the global epidemiology of HIV of this magnitude given the weakness of direct 
measurement of incidence and death should not be surprising. As prevalence surveys became more 
widely available, UNAIDS revised downward their global prevalence estimates by 18% in 2007 and their 
global mortality estimates by nearly 24%.119 Taking into account more data on survival on and off ART as 
well as all-cause mortality data has led to revisions of a similar magnitude. Our revision also suggests 
that there is greater uncertainty for incidence, prevalence and death than previously estimated.  
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Regardless of the specific estimates generated from imperfect data, however, our assessment of 
prevalence continues to point to the very large and steadily growing numbers of infected individuals 
many of whom are in need of antiretroviral therapy. Great progress has been achieved reducing 
infections in children (62.4% reduction since the incidence peak in 2002) due to the scale-up of 
interventions.  The continued 1.7 million new infections per year in adults down 32.7% from the peak of 
the epidemic at the global scale, however, is a stark reminder of the continuing epidemic.   
A key finding that confirms many local, regional and global studies120–125 is that interventions especially 
ART, PMTCT and co-trimoxazole have had a profound effect. Cumulatively 19.1 million years of life have 
been saved since 1996, 5.7 million in developed countries and 13.4 million in developing countries.   The 
ratio of DAH to years of live saved is less than $4500 for the average of the period. Given the very rapid 
increase in years of life saved in 2012 and 2013, the ratio for the period 2000-2013 when DAH figures 
are available will likely be significantly lower. The scale-up, number of lives saved and comparatively low 
price per year of life saved is one of the major achievements in global health in the last decade. Many 
groups, local, national and global, deserve a share of the credit for this accomplishment.  DAH does not 
count national contributions to the cost of HIV programs; real variation in the ratio of the total cost per 
year of life saved is likely much smaller because many middle-income countries receive little DAH and 
fund most HIV interventions from their own resources. Micro-economic studies of the cost per years of 
life saved have also reported wide variation across locations.126–128  We would expect given investments 
in initial program start-up including capital equipment investments that the ratio of DAH to life-years 
saved will decrease overtime. With prevalence growing 5.8% per year over the past 5 years, the need to 
learn from more efficient programs is paramount. Our analysis of survival on ART showed wide variation 
in program outcomes within sub-Saharan Africa. Counterfactual analysis of what might happen if all 
programs achieved the levels of mortality seen in the programs with the best outcomes or even what 
would happen if high-income country on ART death rates were achieved would help shed further light 
on the importance of quality improvement for future HIV death reductions.     Improving cost-
effectiveness of ART programs will require a process of continuously documenting costs, outcomes and 
efficiency along with a mechanism for shared learning across programs on improving quality.  HIV 
infected intravenous drug users have not benefited as much from treatment as those infected through 
sexual transmission. The only regions with an ongoing increase in mortality from HIV in the 2000 to 2013 
period are Asia East, Eastern and Central Europe and North Africa Middle East where large proportions 
of HIV cases are found among intravenous drug users for whom countries may be less inclined to 
provide treatment services. Even in countries with a greater emphasis on harm-reduction strategies 
drug users may still be a more difficult group for health services to reach.129 
Age-standardized tuberculosis mortality rates including tuberculosis in HIV positive individuals at the 
global level changed at -2.8% (-3.6% to -2.2%) per year from 1990 to 2000 and around a percentage 
point faster from 2000 to 2013, -3.7% (-4.4% to -3.0%) per year. When examining tuberculosis mortality 
in individuals who are HIV-negative, the acceleration was smaller from -3.3 (-4.1% to -2.6%) to -3.7% (-
4.4% to -3.0%) change per year but still significant.  There has been comparatively little decline in the 
global age-standardized tuberculosis incidence rate in HIV negative individuals although some regions 
such as South Asia and East Asia have seen accelerated declines since 2000. Prevalence has declined 
much faster than incidence, which is consistent with earlier and more effective treatment shortening 
durations. In addition to shorter duration, the death to incidence ratio changed from 0.36 in 1990 to 
0.18 in 2013 also a likely consequence of treatment. There has been considerable regional and country 
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variation in progress on tuberculosis with the ARC for mortality ranging from -10.3% to 2.5% from 1990 
to 2013 and the ARC for incidence ranging from -3.3% to 2.5% over the same period. This variation 
implies that more rapid progress is possible at the global scale if lessons can be learned from countries 
with more rapid achievement. Since 2000, as for HIV and malaria, global progress in terms of prevalence 
and mortality has accelerated. We are unable to compute the extra years of life saved for tuberculosis as 
we can for HIV; but the comparatively modest DAH for tuberculosis over the period 2000-2011 ($8.3 
billion) has been associated with over this time period with greater reductions in incidence, prevalence 
and death rates. Tuberculosis is different from HIV and malaria in that the rising incidence and death 
rates with age mean that demographic aging of the world’s population in the absence of other changes 
will naturally lead to higher numbers of cases and deaths. Demographic changes in essence slow the 
progress of tuberculosis control; a factor that should be built into considerations of funding and 
program strategy. The established links between alcohol, diabetes, tobacco smoking and tuberculosis 
also mean that trends in these risk factors can modulate trends in tuberculosis.130–132 In this analysis, we 
have not separately examined the incidence, prevalence and mortality related to multi-drug resistant 
tuberculosis (MDR-TB). There are concerns that even in places with substantial declines in tuberculosis 
incidence, prevalence and death such as China, MDR-TB may be a substantial challenge.82,133–136 
Modeling exercises have shown that under certain circumstances MDR-TB could reverse important gains 
made in combatting tuberculosis.82,136,137 Future revisions of the burden of disease should examine more 
carefully the evidence on the levels and trends in MDR-TB.   
Our results for tuberculosis differ from WHO estimates in some important ways. In general, we estimate 
higher mortality, lower prevalence and incidence and a smaller fraction of tuberculosis related to HIV.  
Our estimates of prevalence are driven by the available prevalence surveys and are not back calculated 
from incidence. Our incidence estimates start with case-notifications corrected for missing age-groups 
and case types such as smear-negative pulmonary or extra-pulmonary and expert judgment of the case-
detection rate. For some countries, with implausibly large numbers of smear-negative and extra-
pulmonary cases notified in individuals under 15, we have excluded these data from the analysis.  
However, the Bayesian meta-regression identifies a solution for incidence that is consistent with 
prevalence data and estimates of cause-specific mortality. Because this analysis as undertaken using age 
and sex-specific rates, it also takes into account the changing relationship between incidence, 
prevalence, remission, excess mortality and cause-specific mortality with age and sex. Because true 
incidence in any country is not known, our estimates as well as WHO’s depend on expert judgment on 
the case-detection rate.  Systematic bias in the estimated case-detection rate, particularly for earlier 
time periods, will affect not only the volume of estimated tuberculosis cases and time trends.  India 
accounts for 27.1% (26.3% to 27.9%) of global incident cases in 2013; systematic errors in the estimated 
incidence in India in the 1990s would have a profound effect on global trends.  Perhaps more 
importantly, our assessment of global trends for prevalence and death are similar to WHO but differ for 
incidence. WHO estimates accelerated declines in incidence post 2005 whereas we are estimating at the 
global scale comparatively constant incidence rates.  Since total age-sex-specific case notifications 
reported to WHO for smear-positive pulmonary tuberculosis have continued to increase, 1.1 million in 
2000, 2.3 million in 2005 and 2.5 million in 2012, differences in time trends stem from assumptions 
about the case-detection rate and in our case, the incorporation of information from prevalence surveys 
and all-cause mortality.      
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Malaria burden rose steadily until 2004 and has since declined.  The GFATM, President’s Malaria 
Initiative and other bilateral and private initiatives have spent $11.3 billion in DAH from 2000 to 2011.  
The hypothesis that global action has been an important factor in these declines is highly 
plausible.6,110,138–141 The decline in our assessment is driven by the statistical model fitted to the available 
but sparse verbal autopsy data. Key independent variables in the model that drive this estimated decline 
are the variable on resistance for first line agents and ITN coverage. Noor et al’s142 assessment of trends 
in PfPR from 2000 to 2010 indicate that some countries such as Malawi, Zambia or DRC have had 
substantial scale-up of ITNs with minimal reduction or increases in PfPR.  Explanations for the mismatch 
between ITN scale-up and changes in PfPR could lie in the estimation of both PfPR, ITNs or local factors 
that affect who actually receives and uses ITNs or could be a function of other factors, e.g. climate, 
driving changes over this period. There may also be important threshold or saturation effects for ITNs on 
PfPR.  While the substantial decline in child mortality in the last five years is welcome news, 
understanding the relative role of artemisinin combination therapy (ACT) scale-up and vector control is 
challenging and may well vary by country. The variability in the relationship between ITNs and PfPR at 
the national level emphasize the risks of simply assuming that ITN scale-up at the national level will yield 
the percentage reduction in child death observed in the randomized trials; a strategy employed by Child 
Health Epidemiology Reference Group (CHERG) in their child mortality estimates.  It is also important to 
note that the CHERG models did not include a first-line drug resistance as a covariate. We found this to 
be an important predictor in the Africa models in particular and a key driver of the temporal trend noted 
in this region.       
MDG6 brought global attention to these three diseases, ushering in an unprecedented focus on specific 
diseases in the broader development agenda. Despite many who questioned the wisdom of a focus on 
specific diseases, there has been accelerated progress on HIV, malaria and tuberculosis since 2000. In 
the case of HIV, our estimation strategy allows for direct quantification of years of life saved which have 
been substantial. For tuberculosis and malaria, we observe accelerated reductions in deaths and cases 
compared to the decade before the Millennium Declaration. Rigorously assigning causality to these 
accelerations to the global collective action catalyzed by the Millennium Declaration is beyond the scope 
of this paper and likely impossible given the data limitations. Nevertheless, as governments and the 
global community debate the nature, scope and utility of setting new global targets post-2015, these 
findings should be taken into consideration.   
Our comparative analysis of these three diseases demonstrates marked differences in data gaps and 
measurement challenges. Antenatal clinic sero-surveillance and population surveys in generalized 
epidemics have been a powerful tool for tracking evolution of the HIV epidemic with real data collected 
on an annual basis. Cause of death data in many countries with concentrated epidemics also provides a 
relatively timely way to examine the impact of HIV. On the other hand, national data on the outcome of 
ART is extremely weak. Measures such as retention in care and loss to follow-up are often incomplete 
and difficult to compare across facilities, programs and countries. UNAIDS and our modeling do not 
routinely use national data on treatment outcomes and depend on cohort or published studies. Given 
the huge impact of ART on death and prevalence, more accurate and continuous monitoring of ART 
outcomes and costs must be a high priority. In contrast to HIV, tuberculosis results of treatment for 
those diagnosed is highly standardized and reported to WHO at least through the end of treatment.  
However, real-time data on the evolution of tuberculosis is extremely hard to come by. Case 
notifications can only be interpreted by resorting to expert opinion on the case detection rate and 
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prevalence surveys are infrequent and require large sample sizes. A system analogous to the antenatal 
clinic sero-surveillance for tuberculosis would be possible if new diagnostics emerge that can 
quantitatively assess load of bacilli in an individual who is infected.  Pending such a technological 
advance, more frequent prevalence surveys and perhaps capture-recapture studies82 are the only direct 
measurement available to track evolution of the epidemic. In our study, ARC for incidence and 
prevalence 2000 to 2013 is correlated (0.93). Information on malaria clinical cases and deaths is much 
weaker than for HIV or tuberculosis. Case reports are extraordinarily incomplete. Most death occurs in 
places without vital registration systems. Verbal autopsy is widely believed to exaggerate malaria deaths 
particularly in adults,143–145 given the tendency to overdiagnose malaria in African hospital settings;146–149 
yet our systematic review of validation studies shows low sensitivity (33%) and low specificity (93%). 
Bias is a function of both sensitivity and specificity. If these validation studies that are published are 
correct we may in fact be undercounting not over-counting malaria deaths in adults and children in 
areas with substantial malaria and the reverse in areas with relatively little malaria. The only 
comparatively easy to measure outcome related to malaria is the Plasmodium falciparum parasite rate.  
Local surveys have been usefully collated and analyzed by Noor et al and the Malaria Atlas Project.142 
These provide hard evidence on the trends in a measurable outcome; the challenge is that there is a 
relatively loose relationship in the available data between PfPR and incidence or mortality. Given how 
important malaria is, the state of monitoring systems for malaria burden is extraordinarily poor. 
Repeated verbal autopsy studies combined with carefully designed validation studies would be helpful. 
Better data on the incidence of clinical episodes confirmed with rapid diagnostic tests and how it varies 
as a function of the PfPR would improve incidence estimation.  
The three diseases highlight the difference between ICD assigned underlying cause of death and the 
total mortality attributable to a disease including through pathways where a disease aggravates other 
conditions. ICD rules treat conditions -not just these three diseases- in this regard in markedly different 
ways. All deaths directly related to pregnancy and childbirth and any deaths aggravated by pregnancy 
are counted as maternal deaths. For HIV, all deaths in individuals who are HIV-positive are assigned to 
HIV unless they are due to completely incidental causes such as a road traffic injury. Following this 
convention, tuberculosis deaths in HIV positives are assigned to HIV not tuberculosis. In the case of 
malaria, there has long been the recognition that malaria may increase the risk of death in children and 
adults from other causes150–152 such as septicemia or chronic kidney disease. Early studies after the 
eradication or rapid control of malaria documented rapid changes in deaths from pneumonia, and 
chronic kidney disease153,154 suggesting the full effects of malaria on mortality are greater than the ICD 
coded malaria deaths. The ITN RCTs based on verbal autopsy documented that approximately half of the 
declines in under-five mortality were in causes other than malaria assigned through a VA.155,156  It is 
important to recognize that our understanding of the magnitude of each disease is influenced by the at 
times arbitrary rules governing assigning causes of death.   
There are two important general observations from our analysis of HIV compared to prior analyses that 
may be relevant to other diseases. First, we find that concentrated epidemics have been systematically 
over-estimated by a factor on average of more than two. Over-estimation is most likely related to a 
tendency to over-estimate the size of high-risk groups for which there is little information. Why would 
expert judgment be on average so wrong? The disconnect in many countries between expert judgment 
and the results emerging from the analysis of cause of death data should caution us in the future from 
too much dependence on expert judgment in descriptive epidemiology. Second, we find a systematic 
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under-estimation of uncertainty in many countries in the UNAIDS analysis. Their assessment for South 
Africa, for example, had for 2010 an uncertainty interval with a coefficient of variation of 0.03. Our 
assessment prior to matching on all-cause mortality had a coefficient of variation almost six times higher 
(0.19) in the same year.  There is a general tendency, we believe, in many modeling efforts to 
underestimate uncertainty when arbitrary assumptions about parameters are made. For example, the 
default assumptions for uncertainty in the UNAIDS Spectrum model is a coefficient of variation 0.05 for 
mortality on and off ART.  We find from our empirical analysis coefficients of variation that range from 
0.44 in age group 15 to 24 and CD4 count greater than 500 to 1.00 in age-group 45 and above and CD4 
count greater than 500. In other words, uncertainty in these parameters appears to have been under-
estimated by an order of magnitude. This is not a critique of the UNAIDS Spectrum modeling effort 
rather a reminder that statistical analysis of parameter uncertainty often reveals that we know much 
less than we think.   
Our analysis of HIV in India based on the 2005-2006 National Family Health Survey and antenatal clinic 
sero-surveillance suggests that in 2002 there were 287 thousand (199 thousand to 377 thousand) 
deaths. Cause of death data, however, are available from several sources all pointing to substantially 
lower numbers of deaths than then UNAIDS high-risk group analysis. The Million Death Study reported 
using data for 2001-2003 estimated 59,000 to 140,000 deaths in 2004. The urban Medical Certification 
of Causes of Death system recorded a peak age-standardized death rate in 6.3 per 100,000 equivalent at 
the national level to 57 thousand deaths. We did not use these sources in our assessment, the 
substantial mismatch between our estimates highlights the need for improved understanding of causes 
of death in India.       
Some global health efforts to develop robust estimates of the burden of disease sometimes end up 
using both empirical measurement on incidence, prevalence and cause-specific mortality plus coverage 
of interventions and assumed effectiveness of interventions. The blending of real measurement of 
outcome and assumed mapping of interventions to outcome is justified because recent scale-up of 
interventions may not be reflected in the sparse measurements that are available. Our assessments 
used the modified Spectrum model to map ART coverage into likely changes in mortality from HIV.  
These are supported in some countries by measured declines in all-cause mortality or cause-specific 
mortality but in other countries are entirely based on the presumed relationship between intervention 
roll-out and mortality. Examples abound of this blending of data on outcome and intervention coverage: 
CHERG estimates of declines in child deaths due to ITNs and Hemophilus influenza type B vaccine 
coverage are not based on any statistical relationship observed but on the assumption that 
interventions will yield the declines seen in randomized trials. These are reasonable assumptions but 
there is a fundamental difference between observing the change in outcome as opposed to assuming 
the outcome has changed; this difference is not immediately evident in global health estimation efforts.  
It can yield circular analyses where estimates are used by other authors to evaluate impact. In general in 
the GBD 2013, we have sought to largely use empirical data and statistical associations seen in the data 
to make estimates.  But for HIV in particular, we have used the approach embodied in Spectrum.   
This analysis of data on HIV, tuberculosis and malaria has many limitations given the ambition to track 
incidence, prevalence and mortality for 188 countries from 1990 to 2013.  First, ART estimates for 2013 
are actually highly preliminary.  Countries have reported ART scale-up up through 2012 and provided 
estimates for 2013.  Many of these estimates were aspirational and we have used growth rates over the 
five years 2008-2012 to adjust these 2013 estimates. Second, we have not independently validated the 
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country reports of ART scale-up. We have added to the uncertainty by randomly varying ART scale up by 
sampling a uniform distribution from plus to minus 10% but this presumes that on average ART scale-up 
is not exaggerated. Third, we have used 102 studies on ART outcomes to inform our assumptions of 
death rates on ART. There is marked variation across sites. More recent programs may be achieving 
better outcomes than the published literature if there has been shared learning across programs.  The 
published literature may be biased towards better outcomes through the publication bias; poor 
programs are unlikely to seek to publish their results. There was insufficient national data to use local 
information for each country on ART programs. Our estimates may be biased up or down for a particular 
country because local ART outcomes may be better or worse than the sub-Saharan Africa average. 
Future rounds of estimation will be substantially improved by more robust ART treatment outcome data 
collected from nationally representative samples of ART patients across a wider array of countries.  
Fourth, we have sought to find epidemic curves for the major generalized epidemics that are both 
consistent with available prevalence data and all-cause mortality data derived from sources such as vital 
registration or sibling histories in household surveys. The process of matching all-cause mortality draws 
and Spectrum outputs that are consistent also substantially reduces uncertainty. Given the mismatch of 
these data sources, we are likely underestimating uncertainty in these countries. Fifth, we have not 
modified the UNAIDS assumptions for survival in children infected with HIV. However, published studies 
from high-income countries pre-ART suggest much higher survival.157 Our estimates of death in the age-
groups 5-9 and 10-14 may therefore be exaggerated. Sixth, our estimates of uncertainty for HIV may be 
under-estimated because some of our uncertainty ranges for parameter inputs have been selected 
arbitrarily and true variation for example in age-sex patterns of incidence may be larger. This is 
supported by the number of country-age-sex years where our estimates of prevalence are different than 
available national prevalence surveys. Seventh, based on debate on the burden of malaria in adults, we 
have chosen to not redistribute garbage code deaths onto malaria in verbal autopsy studies in adults.  
This leads to a reduction in the estimated number of adult malaria deaths. While this choice is 
motivated by expert opinion, it is not based on any direct data. Even without the redistribution of 
garbage codes, the percentage of deaths occurring in adults in Africa is still high and has to be 
interpreted with caution given the potential for misclassification bias in verbal autopsies. On the other 
hand, the choice not to redistribute ill-defined codes onto malaria may bias our adult deaths 
downwards. Eighth, Noor et al.  have recently published PfPR for 2000 and 2010.142  A full time series of 
PfPR would be a useful covariate for modeling the burden of malaria.  The Malaria Atlas Project is 
working on this time series analysis of PfPR and when it is finalized it would strengthen the analysis of 
malaria trends. Ninth, our uncertainty intervals for malaria incidence and mortality reflect sampling, 
non-sampling uncertainty and model specification uncertainty but do not reflect the uncertainty that 
may stem from misclassification biases in verbal autopsy.  Uncertainty is likely underestimated due to 
the limitations of VA for malaria in children and adults. Tenth, other studies in countries such as the 
Gambia suggest substantial declines in malaria in these settings; in our analysis of mortality, however, 
these types of studies have not been used.158,159 Eleventh, our analysis of tuberculosis assumes that local 
expert judgment about the case-detection rate is unbiased; this assumption, however, may be incorrect 
with some countries with higher or lower case-detection rates. Twelfth, our uncertainty intervals for 
tuberculosis incidence and prevalence generated from DisMod-MR 2.0 are likely underestimated. The 
intervals are narrow because we have extensive data inputs for essentially all countries in the form of 
adjusted case-notifications and CODEm estimates of all-cause mortality. While each data point has 
considerable uncertainty, the meta-regression produces narrow estimates of the predicted mean value 
Confidential draft. Please do not cite or circulate.
for an age, sex, country-year because of the extensive and often consistent data. These intervals do not 
capture the potential for systematic error in some of the data processing steps such as the use of the 
expert-based case-detection rate.   Despite these important limitations, the GBD approach has many 
advantages primarily because it is a comprehensive and clearly documented approach to disease burden 
estimation that examine all the available data and invests substantial effort in standardization of 
definitions, data adjustments and modeling across all diseases and injuries.   
The focus of the global health community on action to  reduce HIV/AIDS, tuberculosis and malaria , 
enshrined in MDG6, was not only appropriate in 2000 at the Millennium Declaration, but is increasingly 
relevant today given the slow, but important progress that disease control strategies have yielded, 
particularly in recent years. Much remains to be done, however, while there is now evidence that the 
implementation of known interventions is beginning to have an effect, it is probably less than is widely 
believed, or hoped. But these interventions are working , and need to be rapidly scaled up with more 
funding, more emphasis on national health system strengthening in key affected countries to increase 
access to them by the poor, and more targeted research to accelerate progress. What is also clear from 
this analysis as we enter the final phase of the MDG era is how little we reliably know in many countries 
to track progress. Rapidly  reducing the massive uncertainty that surrounds the measurement of these 
diseases, particularly malaria, will be essential if we are to better monitor, and respond to evidence 
about progress, or not, with their control. Author Contributions 
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Figure 1. UNAIDS compartmental model for estimating mortality in HIV positive individuals in the 
absence of ART. 
  
Figure 2. Mean and 95% uncertainty interval for HIV relative survival after seroconversion for age-group 
25-34 based on the analysis of 13 pre-ART cohort studies.  The UNAIDS assumption for survival is shown 
for comparison. 
  
Table 1. HIV-specific mortality rates for 25-34 year olds on ART in sub-Saharan Africa, by time since 
initiation, sex, and initial CD4 count (per 100 person-years)  
 
Figure 3. Vital registration deaths assigned to HIV (red), deaths coded to garbage codes redistributed to 
HIV (blue), and deaths misclassified reassigned to HIV (green) in Thailand (a) and the Russian Federation 
(b) in 2005. 
  
Figure 4. Vital registration inputs, and Spectrum and UNAIDS HIV mortality draws for Panama. 
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Figure 5. Bayesian meta-regression estimates for tuberculosis incidence, prevalence, remission, excess 
mortality, and cause-specific mortality for Kenya 2013.  For each observation in grey, the width of the 
bar refers to the age interval of the observation and the height the uncertainty interval.  To stabilize 
estimates, all data from 2008-2013 are included. 
  
Figure 6. Meta-analysis of published validation studies of verbal autopsy for malaria in adults (a) and 
children (b). 
  
Figure 7. Estimated global incidence (a), prevalence (b) and mortality (c) of HIV with 95% uncertainty 
intervals, 1990-2013. UNAIDS estimates shown for comparison. 
  
Figure 8. Age-sex distribution of new HIV infections (a) and deaths (b) in 2013. 
  
Table 2. Age-standardized HIV/AIDS incidence, prevalence, and mortality rates (per 100 000) and 
annualized rates of change (%), with 95% UI, for 21 GBD regions. 
  
Figure 9. Age-standardized HIV incidence (a), prevalence (b) and mortality (c) in 2013. Rates per 100 000 
population.  
  
Table 3. HIV/AIDS incidence and deaths for all ages by sex and combined and annualized rates of change 
(%), with 95% UI, for 21 GBD regions and 188 countries. 
  
Figure 10. Years of life saved (YLS) through ART, PMTCT, and co−trimoxazole prophylaxis by GBD region, 
1990−2003 (A), 2004−2008 (B), and 2009−2013 (c) 
  
Figure 11. Comparison of 43 national HIV prevalence survey results for age groups 15-49 to prevalence 
estimates from the GBD 2013 and UNAIDS for the same year and age-group.  Each point corresponds to 
an estimate for a particular country, survey year, sex, and five-year age group.  The solid line indicates 
the line of equivalence. 
  
Figure 12. Global tuberculosis incident cases (a), prevalent cases (b) and deaths (c) 1990-2013. WHO 
estimates shown for comparison. Both all forms and tuberculosis in HIV negatives are shown. 
  
Figure 13. Age-sex distribution of tuberculosis incident cases (a) and deaths (b) in HIV negatives in 2013. 
  
Table 4. Age-standardized tuberculosis without HIV incidence, prevalence, and mortality rates (per 100 
000) and annualized rates of change (%), with 95% UI, for 21 GBD regions. 
  
Table 5. Tuberculosis without HIV incidence and deaths for all ages by sex and combined and annualized 
rates of change (%), with 95% UI, for 188 countries. 
  
Figure 14. Age-standardized tuberculosis incidence (a) and death rates (b) in HIV negatives in 2013. 
Rates per 100 000 population. 
  
Figure 15. Global malaria cases (a) and deaths (b) with 95% uncertainty intervals. World Malaria Report 
2013 estimates shown for comparison. 
  
Figure 16. Age-sex distribution of malaria cases (a) and deaths (b) in 2013. 
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Table 6. Age-standardized malaria incidence, prevalence, and mortality rates (per 100 000) and 
annualized rates of change (%), with 95% UI, for 16 GBD regions. 
  
Figure 17. Age-standardized malaria incidence (a) and death (b) rates in 2013. Rates per 100 000 
population. 
  
Table 7. Malaria incidence and deaths for all ages by sex and combined and annualized rates of change 
(%), with 95% UI, for 103 countries. 
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l l lSpectrum Draws UNAIDS Draws Vital Registration data
Figure 4. Vital Registration Inputs, Spectrum and UNAIDS Draws − Panama
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Figure 5. Bayesian meta-regression 
estimates for tuberculosis incidence, 
prevalence, remission, excess mortality, 
and cause-specific mortality for Kenya 
2013. For each observation in grey, the 
width of the bar refers to the age 
interval of the observation and the 
height the uncertainty interval. To 
stabilize estimates, all data from 
2008-2013 are included.
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Figure 6a. Meta-analysis of published validation studies of verbal autopsy for 
malaria in adults.
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Figure 6b. Meta-analysis of published validation studies of verbal autopsy for 
malaria in children.
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Figure 7c:
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Figure 8a − Global cases for HIV (with ART) by age and sex in 2013
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Figure 8b − Global deaths for HIV (with ART) by age and sex in 2013
Male
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Figure 9a. Age−standardized HIV incidence in 2013.
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Figure 9b. Age−standardized HIV prevalence in 2013.
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Figure 9c. Age−standardized HIV death rates in 2013.
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Figure 10. Years of life saved (YLS) through ART, PMTCT, and co−trimoxazole 

























































































































































































































































































































































































































































































































































































































Figure 11. Comparison of 43 national HIV prevalence survey results for age groups 15-49 to prevalence estimates from the GBD 2013 and UNAIDS
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Figure 12a:
 Global tuberculosis incident cases 1990−2013. WHO estimates shown for comparison. 
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Figure 12b:
 Global tuberculosis prevalent cases 1990−2013. WHO estimates shown for comparison. 
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Figure 12c:
 Global tuberculosis deaths 1990−2013. WHO estimates shown for comparison. Both all forms and 
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Figure 13a − Global cases for tuberculosis (without HIV) by age and sex in 2013
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Figure 13b − Global deaths for tuberculosis (without HIV) by age and sex in 2013
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Figure 14a. Age−standardized tuberculosis incidence in HIV negatives in 2013.
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Figure 14b. Age−standardized tuberculosis death rates in HIV negatives in 2013
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Figure 15a:
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Figure 15b:
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Figure 16a − Global cases for malaria by age and sex in 2013
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Figure 16b − Global deaths for malaria by age and sex in 2013
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Figure 17a. Age−standardized malaria incidence rates in 2013.
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Figure 17b. Age−standardized malaria death rates in 2013.
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Table 1. HIV-specific  mortality rates for 25-34 year olds on ART in sub-Saharan Africa, by time since 
initiation, sex, and initial CD4 count  (per 100 person-years)
Female Male
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Annualized rate of change (%)
Age-standardized rates 
1990-2000 2000-2013
Table 2. Age-standardized HIV/AIDS incidence, prevalence, and mortality rates (per 100 000) and annualized rates of change (%), with 95% UI, for 21 GBD regions.
Location Incidence Prevalence Mortality
(per 100 000), 2013
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
924 776
(845 603 to 1 104 526)
723 124
(670 708 to 831 754)
922 869
(863 238 to 1 007 549)
617 850
(570 414 to 677 695)
1 847 645
(1 719 830 to 2 101 652)
1 340 974










(57 060 to 104 422)
35 884
(29 743 to 43 334)
20 947
(15 405 to 29 844)
8746
(6465 to 11 375)
95 352
(72 788 to 132 862)
44 630










(777 712 to 1 030 189)
687 240
(636 836 to 792 586)
901 923
(842 259 to 987 825)
609 104
(562 000 to 668 733)
1 752 294
(1 631 535 to 2 014 476)
1 296 344









































































































































































































































































































(14 456 to 45 002)
9317
(7316 to 12 472)
10 968




(20 768 to 64 990)
12 575









China 24 843(13 863 to 44 316)
8988
(7010 to 12 114)
10 822




(20 128 to 64 616)
12 145





















































Table 3. HIV/AIDS incidence and deaths for all ages by sex and combined and annualized rates of change (%), with 95% UI, for 21 GBD regions and 188 countries.
All ages incidence and deaths, 2013 Annualized rate of change (%)
Male Female Total 1990-2000 2000-2013
Location
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28 607
(9 436 to 63 683)
52 794
(41 230 to 70 403)
17 265
(5343 to 30 460)
30 592
(20 739 to 41 289)
45 872
(14 702 to 93 994)
83 387


































































India 18 408(2247 to 23 936)
49 345
(38 882 to 63 680)
12 649
(1845 to 16 944)
29 318
(20 048 to 38 653)
31 057
(4091 to 39 459)
78 662




































(1617 to 54 744)
2422 










(32 957 to 184 964)
38 199
(20 695 to 113 552)
26 753
(10 929 to 87 732)
10 141
(4248 to 36 852)
92 460
(44 216 to 273 917)
48 340




























Indonesia 29 204 (3669 to 127 307)
9846 
(666 to 48 942)
15 954 
(2027 to 70 429)
4601 
(227 to 24 839)
45 159 
(5646 to 194 375)
14 446 


































































Myanmar 3215 (422 to 18 254)
5831 






(557 to 23 177)
6751 















































Thailand 8657 (4349 to 13 097)
9421 






(6320 to 18 644)
11 595 


















































































































(11 695 to 17 898)
10 459
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(30 301 to 58 405)
22 838
(18 002 to 28 949)
11 207




(38 281 to 73 913)
27 662








































































































Russia 30 851 (22 352 to 46 994)
14 423 
(10 797 to 19 740)
6672 




(27 617 to 57 331)
16 138 









Ukraine 8943 (4013 to 14 168)
7670 






(5869 to 20 307)
10 558 
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(18 630 to 28 703)
9521
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(13 687 to 24 490)
8091
(6273 to 10 287)
7958




(19 842 to 35 094)
10 444









Brazil 17 156 (13 016 to 23 725)
7912 
(6086 to 10 130)
7661 




(18 802 to 34 189)
10 217 





































(10 523 to 27 132)
8087






































































































































































































































































































































































































North Africa and Middle East
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20 227
(9394 to 47 347)
7959
(4591 to 11 627)
6193




(12 244 to 61 760)
10 518




























United States 19 503 (8675 to 46 702)
7694 
(4306 to 11 351)
6058 




(11 370 to 60 381)
10 197 












































































































































































































(33 684 to 48 736)
34 484
(29 112 to 40 928)
46 721
(38 841 to 56 310)
33 317
(26 990 to 41 399)
87 241
(73 529 to 104 384)
67 801









Angola 15 931 (11 412 to 21 253)
7668 
(5298 to 10 586)
18 844 
(14 120 to 24 425)
8531 
(6012 to 11 969)
34 775 
(25 849 to 45 207)
16 199 















































Democratic Republic of the 
Congo
17 438 
(13 583 to 22 693)
17 392 
(13 740 to 22 269)
20 175 
(15 383 to 26 302)
17 223 
(13 018 to 23 364)
37 613 
(29 660 to 47 421)
34 615 
















































(239 354 to 285 112)
210 586
(198 215 to 224 774)
322 401
(296 688 to 349 447)
205 015
(189 971 to 222 792)
582 301
(537 558 to 630 227)
415 601
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Ethiopia 15 851 (12 139 to 20 542)
27 417 
(22 586 to 33 072)
19 151 
(14 997 to 24 731)
24 989 
(18 874 to 33 145)
35 002 
(27 389 to 44 699)
52 405 









Kenya 38 877 (33 698 to 43 684)
30 059 
(25 652 to 34 355)
46 716 
(41 140 to 52 977)
26 704 
(21 777 to 31 960)
85 593 
(78 186 to 93 863)
56 763 

















(356 to 11 358)
3722 









Malawi 25 256 (21 686 to 29 780)
21 829 
(19 080 to 24 746)
33 126 
(28 119 to 39 534)
20 006 
(16 290 to 24 470)
58 382 
(51 810 to 67 436)
41 835 




























Mozambique 64 009 (50 297 to 78 047)
35 558 
(30 206 to 40 857)
73 592 
(59 146 to 89 609)
39 419 
(34 459 to 44 370)
137 600 
(109 740 to 165 615)
74 978 










































































(5963 to 18 663)
10 603 









Tanzania 30 308 (24 975 to 37 174)
35 376 
(30 606 to 41 040)
39 352 
(31 857 to 48 818)
33 666 
(26 958 to 40 319)
69 660 
(58 592 to 85 895)
69 041 









Uganda 48 542 (33 485 to 60 232)
26 727 
(22 583 to 31 140)
62 057 
(45 900 to 75 069)
26 212 
(21 621 to 31 785)
110 599 
(80 312 to 133 132)
52 939 









Zambia 20 161 (16 536 to 24 105)
15 695 
(12 805 to 19 018)
29 368 
(24 555 to 34 316)
18 086 
(14 231 to 21 569)
49 529 
(42 630 to 56 376)
33 781 










(198 348 to 248 797)
160 280
(142 399 to 180 385)
280 376
(256 508 to 309 801)
160 992
(133 568 to 185 435)
502 799
(470 822 to 537 266)
321 272




































(12 983 to 17 837)
9173 




























South Africa 175 519 (151 842 to 200 204)
124 429 
(107 696 to 143 955)
221 112 
(198 114 to 249 156)
127 484 
(101 377 to 150 172)
396 631 
(369 966 to 432 109)
251 912 




























Zimbabwe 27 438 (23 254 to 31 845)
23 321 
(19 787 to 27 956)
36 217 
(30 580 to 41 205)
21 874 
(17 670 to 25 549)
63 655 
(55 522 to 71 292)
45 195 










(119 664 to 165 598)
147 892
(131 751 to 171 029)
167 215
(140 949 to 192 831)
152 976
(133 303 to 173 924)
306 975
(263 141 to 356 401)
300 868















































Cameroon 18 364 (14 701 to 22 135)
15 653 
(12 216 to 19 636)
22 103 
(17 903 to 27 084)
15 669 
(12 898 to 18 786)
40 467 
(33 508 to 48 609)
31 322 
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(6804 to 12 391)
8956 









Cote d'Ivoire 11 756 (8303 to 15 969)
14 804 
(11 522 to 18 328)
12 913 
(9713 to 16 926)
11 511 
(8942 to 14 260)
24 670 
(18 594 to 32 159)
26 315 















(5136 to 10 470)
10 775 
(6634 to 15 847)
14 715 



























































































































Nigeria 80 309 (61 339 to 100 239)
83 530 
(70 612 to 104 376)
97 025 
(73 874 to 120 279)
92 271 
(74 817 to 111 822)
177 334 
(140 750 to 223 268)
175 801 
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Incidence Prevalence Mortality Incidence Prevalence Mortality






















































































































































































































































































































































































Table 4. Age-standardized tuberculosis without HIV incidence, prevalence, and mortality rates (per 100 000) and annualized rates of change (%), with 95% UI,  for 21 GBD regions.
Age-standardized rates
(per 100 000), 2013 Annualized rate of change (%)
Location Incidence Prevalence Mortality
1990-2000 2000-2013
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
4 517 530
(4 398 104 to 4 647 059)
835 602
(739 280 to 958 088)
2 545 138
(2 472 904 to 2 621 788)
454 659
(356 953 to 511 449)
7 062 668
(6 885 472 to 7 270 226)
1 290 260










(245 783 to 260 127)
28 495
(23 320 to 30 615)
123 333
(120 187 to 125 954)
10 667
(7961 to 12 027)
376 323
(367 117 to 385 671)
39 162










(4 146 317 to 4 392 574)
807 106
(711 182 to 928 549)
2 421 804
(2 351 014 to 2 497 867)
443 992
(349 210 to 500 700)
6 686 345
(6 511 240 to 6 894 801)
1 251 098


















(78 818 to 83 863)
8994






























































































(100 303 to 106 922)
8782





















































































































































































(762 944 to 818 962)
35 550
(29 728 to 43 445)
371 698
(358 536 to 386 706)
13 158
(11 150 to 16 040)
1 162 888
(1 126 383 to 1 201 277)
48 708









China 732 136 (703 787 to 759 995)
33 391 
(27 605 to 39 691)
335 017 
(322 040 to 350 436)
11 794 
(9908 to 14 032)
1 067 153 
(1 031 846 to 1 104 841)
45 185 















































Table 5. Tuberculosis without HIV incidence and deaths for all ages by sex and combined and annualized rates of change (%), with 95% UI, for 188 countries.
All ages incidence and deaths, 2013 Annualized rate of change (%)
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1 633 772
(1 569 448 to 1 702 317)
400 912
(312 339 to 503 463)
804 753
(774 985 to 836 828)
215 086
(166 711 to 264 425)
2 438 524
(2 353 624 to 2 531 209)
615 998















(3402 to 10 689)
16 697 
(16 178 to 17 247)
9188 









Bangladesh 161 542 (153 701 to 169 490)
12 257 
(9086 to 16 868)
102 951 




(253 273 to 276 373)
15 545 




























India 1 334 126 (1 276 181 to 1 395 002)
356 940 
(271 034 to 454 519)
581 851 
(556 873 to 607 765)
188 577 
(141 824 to 238 149)
1 915 977 
(1 843 861 to 1 993 731)
545 516 

















(30 084 to 32 938)
8162 









Pakistan 117 080 (111 322 to 122 526)
23 311 
(16 082 to 32 229)
108 413 
(103 577 to 113 108)
14 188 
(8804 to 19 462)
225 493 
(216 308 to 234 231)
37 499 










(520 045 to 558 187)
130 046
(109 419 to 150 362)
321 035
(311 259 to 330 942)
63 824
(40 144 to 75 348)
862 726
(833 162 to 886 678)
193 870




























Indonesia 186 734 (175 949 to 195 308)
71 151 
(53 474 to 85 108)
154 066 
(147 342 to 160 217)
37 572 
(15 822 to 47 009)
340 799 
(325 302 to 352 949)
108 723 


































































Myanmar 59 000 (53 067 to 61 680)
17 233 
(9964 to 26 771)
30 437 
(29 213 to 31 605)
6523 
(3695 to 10 706)
89 437 
(83 011 to 92 987)
23 756 









Philippines 114 611 (110 488 to 119 351)
21 116 
(16 010 to 28 500)
51 534 
(49 589 to 53 349)
8162 
(5945 to 10 868)
166 145 
(160 384 to 172 007)
29 278 




































(67 488 to 73 756)
9152 




























Vietnam 81 050 (77 670 to 84 298)
8851 
(6374 to 12 124)
28 599 




(105 506 to 113 534)
14 021 
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(127 584 to 139 310)
17 428
(11 652 to 19 299)
54 525




(181 006 to 194 926)
21 372








































































































Russia 99 009 (94 194 to 103 393)
12 075 
(8364 to 13 569)
41 613 




(135 057 to 146 053)
14 829 
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(83 903 to 88 660)
8299
(7259 to 10 104)
68 242




(150 668 to 158 377)
15 219
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11 875

























































































































































































































































(107 911 to 120 891)
33 525
(25 993 to 41 648)
87 499
(82 703 to 92 494)
17 485
(13 887 to 21 598)
202 070
(191 398 to 212 432)
51 009

















(32 403 to 37 070)
8832 















































Democratic Republic of the 
Congo
79 732 
(74 757 to 84 369)
23 672 
(17 122 to 31 677)
60 129 
(56 560 to 63 798)
12 414 
(9525 to 15 979)
139 861 
(132 598 to 147 281)
36 085 
















































(307 524 to 347 855)
100 724
(81 254 to 111 357)
227 786
(214 817 to 242 641)
70 740
(56 858 to 78 604)
553 891
(522 812 to 589 662)
171 464

















(12 704 to 14 335)
7572 
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Ethiopia 65 303 (60 948 to 69 848)
29 593 
(23 362 to 36 203)
51 751 
(48 490 to 54 753)
20 595 
(16 355 to 25 142)
117 053 
(110 158 to 124 123)
50 188 









Kenya 61 605 (56 119 to 67 928)
11 395 
(8667 to 14 118)
44 251 




(96 915 to 115 666)
17 898 


































































Mozambique 29 668 (25 448 to 34 673)
9214 
(7203 to 11 545)
16 854 




(39 804 to 53 743)
14 950 























































(19 605 to 21 824)
8667 

















(14 087 to 16 764)
8378 









Tanzania 23 582 (21 502 to 25 681)
10 942 
(7615 to 14 080)
16 759 
(15 183 to 18 327)
9099 
(6309 to 11 620)
40 341 
(36 939 to 43 710)
20 041 









Uganda 28 674 (25 605 to 31 944)
8923 
(5823 to 11 569)
18 418 




(42 791 to 52 231)
14 738 

















(40 875 to 53 310)
8957 










(241 833 to 311 989)
23 357
(19 033 to 27 878)
237 413
(209 522 to 273 154)
13 252
(10 527 to 16 642)
509 674
(455 681 to 580 571)
36 609


































































South Africa 217 545 (192 039 to 249 900)
13 138 
(10 056 to 16 480)
190 831 




(363 668 to 466 379)
19 918 




































(60 653 to 78 743)
8905 










(242 139 to 268 854)
53 088
(43 739 to 65 410)
149 320
(141 150 to 157 043)
34 426
(29 093 to 40 604)
404 527
(384 745 to 425 437)
87 515
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Nigeria 97 302 (89 158 to 105 772)
22 730 
(15 211 to 31 509)
59 901 
(54 701 to 65 227)
14 719 
(10 135 to 20 468)
157 203 
(145 193 to 169 957)
37 449 
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Incidence Mortality Incidence Mortality
Global 2360·42 (1373·81 to 4051·98)
11·78
 (9·69 to 14·21)
0·26
 (-1·02 to 1·12)
1·96
 (0·84 to 3·06)
-3·27
 (-4·99 to -1·18)
-3·11
 (-4·72 to -1·60)
High-income Asia Pacific 0·40 (0·34 to 0·47)
0·00
 (0·00 to 0·00)
-8·48
 (-9·93 to -7·09)
-18·55
 (-19·35 to -17·73)
-1·67
 (-2·28 to -1·18)
-16·79
 (-17·75 to -15·86)
Central Asia 0·19 (0·16 to 0·21)
0·02
 (0·01 to 0·03)
16·77
 (15·48 to 18·21)
-4·84
 (-9·03 to -0·29)
-38·41
 (-39·92 to -37·09)
-7·32
 (-10·76 to -3·15)
East Asia 0·23 (0·20 to 0·25)
0·01
 (0·01 to 0·01)
-0·60
 (-1·44 to 0·36)
-7·67
 (-9·34 to -6·02)
-19·91
 (-20·96 to -18·98)
-10·95
 (-13·09 to -8·36)
South Asia 4428·64 (1639·86 to 10 388·82)
9·08
 (7·00 to 11·73)
-2·00
 (-3·78 to -0·81)
-2·65
 (-4·27 to -0·91)
-3·33
 (-4·67 to -1·81)
-3·39
 (-5·45 to -1·31)
Southeast Asia 1231·49 (556·12 to 2635·04)
2·28
 (1·68 to 3·15)
-3·89
 (-5·56 to -2·16)
-4·54
 (-6·53 to -2·65)
-5·88
 (-8·59 to -3·01)
-6·89
 (-9·01 to -4·25)
Caribbean 245·54 (227·17 to 263·02)
0·91
 (0·51 to 1·47)
-3·35
 (-3·63 to -3·05)
-4·52
 (-6·90 to -1·78)
-4·08
 (-4·64 to -3·53)
-7·48
 (-11·51 to -3·38)
Andean Latin America 49·36 (42·60 to 55·80)
0·04
 (0·03 to 0·05)
-2·53
 (-3·04 to -2·04)
-5·70
 (-7·28 to -4·09)
-2·79
 (-3·64 to -2·05)
-13·80
 (-15·92 to -11·45)
Central Latin America 46·12 (40·32 to 51·63)
0·05
 (0·04 to 0·07)
-2·29
 (-2·75 to -1·85)
-5·58
 (-7·13 to -4·18)
-2·10
 (-2·76 to -1·51)
-10·06
 (-12·13 to -7·34)
Southern Latin America 0·95 (0·81 to 1·08)
0·00
 (0·00 to 0·00)
-9·52
 (-10·71 to -8·32)
-16·26
 (-17·13 to -15·40)
-3·21
 (-4·06 to -2·48)
-16·29
 (-17·17 to -15·43)
Tropical Latin America 62·80 (53·39 to 71·76)
0·03
 (0·02 to 0·05)
-6·49
 (-7·87 to -5·20)
-17·58
 (-19·80 to -15·41)
-0·11
 (-0·50 to 0·21)
-9·20
 (-12·22 to -5·86)
North Africa and Middle East 396·71 (122·46 to 1028·80)
1·97
 (1·07 to 3·48)
2·14
 (1·31 to 3·18)
3·88
 (0·73 to 7·01)
-5·74
 (-9·08 to -2·40)
-7·07
 (-10·62 to -3·04)
Oceania 10 452·65 (3908·47 to 25 253·80)
20·54
 (11·95 to 33·16)
-0·02
 (-0·25 to 0·19)
-0·30
 (-3·70 to 2·75)
-2·14
 (-3·14 to -1·05)
-2·61
 (-5·49 to 0·65)
Central Sub-Saharan Africa 6628·47 (3171·03 to 13 240·91)
43·15
 (28·36 to 63·55)
-2·74
 (-4·45 to -1·39)
-1·59
 (-4·08 to 1·08)
-5·13
 (-7·81 to -2·43)
-5·73
 (-9·03 to -2·28)
Eastern Sub-Saharan Africa 6411·66 (3214·47 to 12 802·02)
39·58
 (33·03 to 49·36)
0·41
 (-0·29 to 1·52)
0·77
 (-0·82 to 2·33)
-6·68
 (-8·94 to -3·58)
-6·76
 (-8·47 to -4·40)
Southern Sub-Saharan Africa 766·01 (315·25 to 1807·70)
4·21
 (3·22 to 5·76)
2·84
 (1·28 to 4·19)
2·85
 (-0·40 to 5·45)
-5·63
 (-8·37 to -2·64)
-7·30
 (-9·74 to -4·10)
Western Sub-Saharan Africa 11 874·88 (6907·10 to 20 684·35)
85·89
 (68·14 to 105·95)
0·90
 (0·26 to 1·72)
1·45
 (-0·24 to 3·18)
-3·79
 (-5·33 to -2·00)
-3·40
 (-5·15 to -1·56)
Table 6. Age-standardized malaria incidence and mortality rates (per 100 000) and annualized rates of change (%), with 95% UI, for 16 GBD regions.
Age-standardized rates
(per 100 000), 2013 Annualized rate of change (%)
Location Incidence Mortality
1990-2000 2000-2013
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Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths Incidence Deaths
80 442 176
(46 673 036 to 138 440 048)
434 792
(337 311 to 564 653)
84 487 696
(48 637 128 to 145 153 824)
419 777
(341 821 to 517 091)
164 929 872
(95 399 904 to 284 354 624)
854 568
(702 884 to 1 032 471)
0·26
 (-1·02 to 1·12)
1·96
 (0·84 to 3·06)
-3·27
 (-4·99 to -1·18)
-3·11






















(46 672 684 to 138 439 696)
434 792
(337 311 to 564 653)
84 487 336
(48 636 776 to 145 153 472)
419 776
(341 820 to 517 091)
164 929 152
(95 399 192 to 284 353 920)
854 568






















 (-9·93 to -7·09)
-18·55
 (-19·35 to -17·73)
-1·67
 (-2·28 to -1·18)
-16·79
 (-17·75 to -15·86)
































 (15·48 to 18·21)
-4·84
 (-9·03 to -0·29)
-38·41
 (-39·92 to -37·09)
-7·32
 (-10·76 to -3·15)


















































































































































 (-1·44 to 0·36)
-7·67
 (-9·34 to -6·02)
-19·91
 (-20·96 to -18·98)
-10·95
 (-13·09 to -8·36)







































(10 587 800 to 67 635 616)
56 349
(37 151 to 77 226)
33 373 982
(13 386 620 to 76 448 012)
65 428
(48 800 to 88 397)
61 849 284
(24 099 755 to 145 007 704)
121 777
(95 871 to 155 492)
-2·00
 (-3·78 to -0·81)
-2·65
 (-4·27 to -0·91)
-3·33
 (-4·67 to -1·81)
-3·39
 (-5·45 to -1·31)

























































India 27 961 284 (10 074 561 to 67 098 740)
54 179 
(35 494 to 74 975)
32 739 706
(12 716 841 to 75 811 540)
62 143 
(45 048 to 85 171)
60 700 992
(22 931 083 to 143 871 240)
116 322 
















































(1 852 612 to 8 988 789)
7763
(5510 to 10 731)
3 646 243




(3 535 079 to 16 619 553)
14 217
(10 315 to 19 781)
-3·89
 (-5·56 to -2·16)
-4·54
 (-6·53 to -2·65)
-5·88
 (-8·59 to -3·01)
-6·89
 (-9·01 to -4·25)























Table 7. Malaria incidence and deaths for all ages by sex and combined and annualized rates of change (%), with 95% UI, for 105 countries.
All ages incidence and deaths, 2013 Annualized rate of change (%)
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(158 478 to 3 289 462)
1341 
(1002 to 1749)
2 003 831 

















































Myanmar 2 459 973 (906 379 to 5 902 743)
4834 
(2817 to 7915)
2 156 398 
(835 746 to 4 950 837)
4322 
(2610 to 7099)
4 616 371 
(1 764 904 to 10 800 000)
9155 





















































































































 (-3·63 to -3·05)
-4·52
 (-6·90 to -1·78)
-4·08
 (-4·64 to -3·53)
-7·48
 (-11·51 to -3·38)



















































































































































 (-3·04 to -2·04)
-5·70
 (-7·28 to -4·09)
-2·79
 (-3·64 to -2·05)
-13·80
 (-15·92 to -11·45)






































































 (-2·75 to -1·85)
-5·58
 (-7·13 to -4·18)
-2·10
 (-2·76 to -1·51)
-10·06
 (-12·13 to -7·34)
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 (-10·71 to -8·32)
-16·26
 (-17·13 to -15·40)
-3·21
 (-4·06 to -2·48)
-16·29
 (-17·17 to -15·43)
































 (-7·87 to -5·20)
-17·58
 (-19·80 to -15·41)
-0·11
 (-0·50 to 0·21)
-9·20
 (-12·22 to -5·86)







































(382 396 to 3 243 600)
5900
(2915 to 11 443)
857 057




(638 796 to 5 569 750)
10 604
(5415 to 19 759)
2·14
 (1·31 to 3·18)
3·88
 (0·73 to 7·01)
-5·74
 (-9·08 to -2·40)
-7·07
 (-10·62 to -3·04)






















































































































(78 799 to 1 177 901)
2203 
(605 to 5384)
1 056 050 
(275 911 to 2 940 472)
5363 



















































(161 967 to 1 225 111)
2483 
(941 to 5133)
1 054 601 
(355 535 to 2 646 959)
5196 






















 (-0·25 to 0·19)
-0·30
 (-3·70 to 2·75)
-2·14
 (-3·14 to -1·05)
-2·61
 (-5·49 to 0·65)


























































(1 939 904 to 7 688 653)
28 851
(16 111 to 49 729)
4 301 690
(2 303 019 to 7 982 794)
31 817
(15 802 to 64 045)
8 241 820
(4 297 149 to 15 640 374)
60 667
(35 115 to 99 000)
-2·74
 (-4·45 to -1·39)
-1·59
 (-4·08 to 1·08)
-5·13
 (-7·81 to -2·43)
-5·73
 (-9·03 to -2·28)
Angola 778 653 (352 510 to 1 612 440)
5421 
(2082 to 12 081)
638 443 
(292 224 to 1 338 115)
5240 
(1083 to 12 889)
1 417 096 
(646 248 to 2 901 702)
10 661 






























North Africa and Middle East
Oceania
Central Sub-Saharan Africa
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Democratic Republic of the Cong 2 641 315 (1 317 961 to 5 137 603)
20 087 
(9338 to 38 586)
3 087 537 
(1 663 453 to 5 670 932)
22 827 
(9178 to 50 451)
5 728 853 
(3 000 717 to 10 800 000)
42 914 
















































(6 544 247 to 24 090 664)
85 566
(65 168 to 109 586)
13 377 215
(7 291 825 to 24 578 200)
89 820
(66 224 to 130 417)
25 897 270
(13 782 158 to 48 529 276)
175 387
(140 361 to 221 113)
0·41
 (-0·29 to 1·52)
0·77
 (-0·82 to 2·33)
-6·68
 (-8·94 to -3·58)
-6·76
 (-8·47 to -4·40)




(446 217 to 1 124 371)
5920 
(3022 to 9518)
1 314 379 
(807 412 to 2 096 773)
11 282 


































































Ethiopia 1 638 589 (498 186 to 4 270 533)
9877 
(5029 to 17 293)
1 182 333 
(373 552 to 3 267 067)
8510 
(3506 to 16 787)
2 820 922 
(876 846 to 7 716 426)
18 387 













(175 809 to 1 772 853)
3896 
(1826 to 8102)
1 409 706 
(412 893 to 3 805 649)
8360 













(212 737 to 1 430 807)
2783 
(1420 to 4868)
1 071 751 






























Mozambique 2 773 504 (1 582 152 to 4 911 657)
19 196 
(13 650 to 25 948)
3 244 189 
(1 684 669 to 6 325 806)
20 473 
(14 753 to 26 654)
6 017 693 
(3 266 015 to 11 100 000)
39 669 




































(409 498 to 1 610 977)
6120 




























Tanzania 1 873 958 (934 095 to 3 672 184)
13 495 
(7362 to 22 215)
2 307 766 
(1 239 301 to 4 260 696)
16 242 
(7989 to 32 819)
4 181 724 
(2 178 550 to 7 920 536)
29 737 









Uganda 1 918 386 (1 036 770 to 3 491 911)
14 247 
(7967 to 22 532)
2 262 354 
(1 245 502 to 4 007 412)
15 298 
(8111 to 25 181)
4 180 741 
(2 285 851 to 7 474 431)
29 545 









Zambia 945 622 (525 219 to 1 635 147)
6667 
(4445 to 9435)
1 077 049 
(585 683 to 1 925 781)
7145 
(4894 to 10 132)
2 022 671 
(1 112 338 to 3 551 130)
13 812 






















 (1·28 to 4·19)
2·85
 (-0·40 to 5·45)
-5·63
 (-8·37 to -2·64)
-7·30
 (-9·74 to -4·10)
































































































(18 569 128 to 44 034 576)
246 973
(179 298 to 334 725)
27 966 300
(17 623 922 to 43 268 248)
218 875
(160 016 to 281 613)
56 956 048
(36 282 648 to 86 449 152)
465 848
(356 750 to 590 771)
0·90
 (0·26 to 1·72)
1·45
 (-0·24 to 3·18)
-3·79
 (-5·33 to -2·00)
-3·40
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(338 344 to 1 013 545)
4085 
(2429 to 5968)
1 085 882 
(607 392 to 1 908 784)
7689 









Burkina Faso 1 772 734 (1 091 493 to 2 837 545)
12 942 
(8142 to 19 266)
2 068 269 
(1 260 720 to 3 396 651)
14 319 
(9910 to 19 631)
3 841 003 
(2 364 116 to 6 158 591)
27 261 









Cameroon 1 141 115 (640 140 to 2 003 619)
8634 
(4332 to 14 541)
1 528 984 
(911 130 to 2 529 638)
10 703 
(6168 to 17 005)
2 670 100 
(1 556 196 to 4 539 860)
19 336 
































(425 863 to 1 287 409)
5463 
(2674 to 9708)
1 383 698 
(754 840 to 2 472 300)
9835 









Cote d'Ivoire 1 116 108 (616 173 to 1 965 682)
7931 
(3796 to 14 026)
1 270 614 
(746 533 to 2 117 101)
8849 
(4705 to 13 599)
2 386 722 
(1 373 505 to 4 113 535)
16 780 









Ghana 1 131 416 (597 366 to 2 063 095)
7843 
(4899 to 11 682)
1 274 480 
(700 996 to 2 287 354)
8572 
(5486 to 12 246)
2 405 896 
(1 293 177 to 4 322 408)
16 415 









Guinea 850 008 (528 198 to 1 364 161)
6594 
(3882 to 9881)
1 070 541 
(666 679 to 1 678 739)
8003 
(4779 to 11 599)
1 920 549 
(1 202 796 to 3 033 236)
14 597 















































Mali 1 812 025 (1 148 899 to 2 815 056)
16 526 
(9857 to 24 875)
2 412 241 
(1 441 912 to 3 931 845)
19 164 
(11 403 to 27 092)
4 224 267 
(2 612 582 to 6 660 447)
35 690 




























Niger 1 348 843 (837 303 to 2 127 755)
11 564 
(4559 to 20 485)
1 608 928 
(1 030 476 to 2 443 363)
13 869 
(6688 to 21 584)
2 957 771 
(1 877 757 to 4 481 069)
25 433 









Nigeria 16 600 000 (10 700 000 to 25 200 000)
151 794 
(95 928 to 223 806)
13 000 000 
(8 224 059 to 19 900 000)
108 611 
(61 160 to 158 184)
29 700 000 
(19 000 000 to 45 300 000)
260 405 




































(430 550 to 1 917 898)
6570 













(416 276 to 1 092 241)
4775 
(2912 to 6784)
1 197 371 
(749 248 to 1 872 567)
8882 
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